

REVIEW

[View Article Online](#)
[View Journal](#) | [View Issue](#)

Cite this: *RSC Appl. Polym.*, 2024, **2**, 749

The luminous frontier: transformative NIR-IIa fluorescent polymer dots for deep-tissue imaging

Richardson Lawrance,^a Partha Chowdhury,^b Hong-Cheu Lin^{*a,c} and Yang-Hsiang Chan^{*b,c,d}

In the realm of deep-tissue imaging, fluorescence imaging in the second near-infrared window (NIR-II, 1000–1700 nm) has proved to be an emerging tool, allowing scientists to probe biological processes with unprecedented depth. Within the NIR-II window, the NIR-IIa region (1300–1400 nm) has proved to have excellent imaging quality in the NIR-II window. Among the diverse types of NIR-II fluorophores, polymer dots (Pdots) have surfaced as a unique category of probes due to their exceptional properties including exorbitant brightness, excellent photostability, outstanding water dispersibility, and facile structural modification compared to traditional fluorescent molecules. The utilization of NIR-IIa Pdots has also addressed critical limitations in imaging by utilizing the advantages of reduced light scattering, diminished autofluorescence, and decreased light absorption by biospecies. Realizing such remarkable characteristics, this review offers insights into the design of high-performance NIR-IIa Pdots through a comprehensive interplay between chemical structures, photophysical properties, and their application in deep-tissue imaging.

Received 29th February 2024,
Accepted 6th June 2024

DOI: 10.1039/d4lp00076e

rsc.li/rscapplpolym

1. Introduction

Fluorescence imaging stands out as a pivotal tool in biomedical detection and image-guided surgery that has opened a new window for both fundamental research and clinical practices in the last few decades. Unlike traditional imaging techniques, such as computed tomography (CT),^{1–3} magnetic resonance imaging (MRI),^{3,4} ultrasound (US),^{5,6} positron emission tomography (PET),⁷ and single-photon emission CT (SPECT),^{8,9} fluorescence imaging offers distinct advantages such as non-invasiveness, exceptional spatiotemporal resolution, real-time detection capability and affordability.¹⁰ Over the years, fluorescence imaging has found wide-ranging applications spanning immunofluorescence assays,¹¹ sensing,^{12,13} super-resolution imaging,^{14,15} single molecule imaging,¹⁶ 3D imaging,^{17,18} and image-guided surgery.^{19–21} However, the obstacle hindering the advancement of fluorescence imaging stems from its spectral emission range, especially visible range, which suffers from enhanced tissue scattering and high

autofluorescence, despite its widespread utilization in image-guided surgery both before and during the operation.^{20,22,23}

In recent years, there has been notable attention directed towards fluorescence imaging technology in the near-infrared spectrum, primarily because of its superior resolution, thereby enhancing the quality of *in vivo* imaging.²⁴ However, within the first near-infrared region (NIR-I, 700–900 nm), imaging deep tissues still encounters significant limitations, of which the penetration depth only goes up to a few millimeters from approximately 1 to 6 mm.^{25–30} Fortunately, in 2009, Dai's pioneering research introduced a fresh perspective on bioimaging—an innovative optical range now known as the NIR-II window (1000–1700 nm) demonstrated superior performance in bioimaging.^{31–33} As shown in Fig. 1, the major advantages of the NIR-II window include reduced tissue scattering, and minimal autofluorescence compared to NIR-I, which results in improved imaging depths of approximately 5–20 mm.^{27,34} However, recent phantom studies, revealed that the contrast of *in vivo* imaging followed the water absorption trend, which could be beneficial for acquiring high resolution images. Emission wavelengths of >1300 nm, where water absorption plays a crucial role in enhancing the contrast over scattering in fluorescence images, result in a high signal to background ratio (SBR) and superior resolution.^{35,36} Overall, the dual benefits of longer wavelengths reducing background noise and water absorption contributing to contrast enhancement lead to better resolution in the 1300–1400 nm region, known as the NIR-IIa window.^{35,37,38} These advantages make NIR-IIa imaging

^aDepartment of Materials Science and Engineering, National Yang Ming Chiao Tung University, Hsinchu, 30050 Taiwan. E-mail: richardsonlawrance.chemie@gmail.com, linhc@nycu.edu.tw

^bDepartment of Applied Chemistry, National Yang Ming Chiao Tung University, Hsinchu, 30050 Taiwan. E-mail: yhchan@nycu.edu.tw

^cCenter for Emergent Functional Matter Science, National Yang Ming Chiao Tung University, Hsinchu, 30050 Taiwan

^dDepartment of Medicinal and Applied Chemistry, Kaohsiung Medical University, Kaohsiung, 80708 Taiwan



Fig. 1 (A) Schematic depiction illustrating the interaction between light and biological tissues across a range of wavelengths. (B) Schematic representation of the propagation of light showing lower (on the left) and intermediate (on the right) absorption characteristics within biological tissue, and the resultant SBRs in fluorescence imaging. (C) Water absorption spectrum within the range of 400–1800 nm. (D) Decreased scattering coefficients among various biological tissues and intralipid tissue mimics. (E) Spectrum of autofluorescence observed in mouse liver, spleen, and heart tissue under excitation at 808 nm shown as black, red and blue lines respectively. The inset displays a closer look at the results for longer wavelengths. Reproduced from ref. 39 with permission from American Chemical Society. Copyright © 2020.

particularly useful for numerous biomedical applications, including *in vivo* imaging and other medical assessments.^{35,37}

Since then, fluorophores emitting in the NIR-IIa window or at longer wavelengths have become a cornerstone of fluorescence imaging. Lately, significant efforts have been undertaken to create fluorophores with emission beyond 1300 nm; this includes single-walled carbon nanotubes (SWCNTs),^{31,37} quantum dots (QDs),^{40–43} rare earth-doped nanoparticles (RENPs),^{44–46} small molecule dyes (SMDs),⁴⁷ and organic semi-conducting polymer-based nanoparticles (SPs).^{48–51} However, each has unique benefits and drawbacks that should be carefully considered for certain biomedical imaging applications.^{18,33,52}

NIR-IIa organic dyes outperform inorganic based fluorophores in many aspects, such as facile structural modification and good biocompatibility, low levels of cytotoxicity, suitability for extensive chemical synthesis, and ease of modification.³⁸ However, NIR-IIa organic compounds have highly conjugated scaffolds that contribute to their low water solubility, so encasing dyes in amphiphilic surfactants inside the nanoparticles has been a popular way to get around this problem. Nevertheless, for small organic dye-doped nanoparticles, potential leakage from the encapsulating matrix is still a problem. Hence, polymer dots (Pdots) have been developed as an innovative type of probe that represents a purely organic



class of water-suspendible polymeric nanoparticles typically composed of conjugated polymers or organic dyes embedded within an amphiphilic polymeric matrix. Their highly tuneable optical properties, extraordinary brightness, enhanced photostability, and biocompatibility make them superior to traditional inorganic fluorophores and small molecules.^{53–55} Generally, Pdots can be prepared through various methods, including nanoprecipitation, mini-emulsion polymerization, the self-assembly of amphiphilic block copolymers, or employing a microfluidic technique.^{56–58} Pdots are becoming increasingly recognized as a highly promising category of fluorescent probes, offering great potential for analysis and imaging applications in the field of biology.^{52,59–61} Unfortunately, to date, there remains a scarcity of Pdots exhibiting emission maxima within the NIR-IIa range.^{49,62–65} This limitation is attributed to the energy gap principle, which indicates that nonradiative decay processes are expedited through vibrational interactions between the ground and excited states due to the narrow energy gap, and hence, a very low quantum yield (QY).^{60,66} However, these limitations can be overcome if the molecular design follows the right fundamental design strategy, which is described in detail in the later part of this review.

In this review, we highlight the most recent developments in Pdots emitting in the NIR-IIa range. Moreover, we discuss existing molecular scaffolds and the strategies to extend the emission wavelengths to the NIR-IIa window. Next, the fundamental obstacle of this window, *i.e.*, brightness, is thoroughly discussed throughout the manuscript. We separately elaborate the two classes of organic dyes (small molecules and Pdots) and their advantages/disadvantage in terms of bio-imaging applications. Finally, the potential application of NIR-IIa fluorophores in blood vessels and tumour imaging is compared with NIR-II dyes with emission <1300 nm and systematically explained for a better understanding of the advantages of the NIR-IIa region over other imaging windows. Last but not least, we mention the possible challenges and future outlook that could be impactful for the future development of NIR-IIa fluorophores, to the best of our knowledge.

2. Molecular engineering of organic fluorophores to attain NIR-IIa emission

NIR-IIa emissive fluorophores in the 1300–1400 nm region are a significant development that overcomes the drawbacks of NIR-I and NIR-II and opens the door to previously unattainable depths in non-invasive imaging and diagnostic applications.⁶¹ In this context, NIR-IIa organic fluorophores, comprising both small molecules and semiconducting polymers, have attracted considerable attention owing to their excellent biocompatibility, versatile molecular design, and the ability to finely tune their optical properties.³⁸ Until now, numerous methodologies have been systematically employed to intricately modify the chemical backbones of organic fluorophores (Fig. 2). These strategic modifications aim to extend the spectral range, enabling desirable absorption and emission of light at longer



Fig. 2 Schematic representation of a universal scaffold for (A) D-A-D and (B) polymethine based fluorophores.

wavelengths.⁶⁷ Conventionally, the engineering of these fluorophores is contingent upon the difference in energy between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO), a correlation intricately governed by their π -conjugated systems.^{66,68} Practical approaches for molecular engineering, which include the extension of conjugation,^{52,67} enhancement of electron density in donor units,⁶⁹ reduction of electron density in acceptor units,⁷⁰ heteroatom exchange,⁷¹ and J-aggregate formation,⁷² have surfaced as efficacious strategies for inducing a red-shifted absorption/emission wavelength of a given fluorophore. For example, extension of the conjugation chain length delocalizes π electrons into the molecular backbone, resulting in a redshift of both absorption and emission due to reducing the HOMO–LUMO gap.^{49,73,74} To further manipulate the electron density of donor units, ingenious approaches involving the introduction of electron-donating substituents have been successfully employed.⁶⁹ Concurrently, strategies for diminishing the electron density of acceptor units have been explored, including tactics such as exploiting the heavy atom effect (*e.g.*, substituting O for Si, S for Se), integrating electron-withdrawing substituents, and introducing fluorine atoms.^{71,75} These meticulous adjustments are instrumental in sculpting the desired properties of fluorophores. The incorporation/replacement of heteroatoms into the fluorophore structure stands out as a pivotal avenue for modulating electron density and, consequently, influencing the energy gap. This deliberate modifi-



cation manifests as bathochromic shifts in absorption and emission wavelengths. Specifically, substituting the oxygen atom of a heterocycle for a carbon, silicon or other chalcogen atom emerges as a particularly effective strategy, inducing a discernible redshift in the absorption/emission spectrum.⁷¹ Furthermore, the creation of J-aggregates emerges as an intriguing facet in this scientific narrative. These aggregates, fabricated through the judicious aggregation of monomer fluorophores *via* π - π interactions between adjacent conjugated units, exhibit redshifted absorption and emission. This distinctive feature underscores the potential of J-aggregates as a valuable tool for achieving desired shifts in spectral characteristics.^{72,76} Together, these strategic modifications form a comprehensive framework for meticulously fine-tuning the chemical properties inherent in organic fluorophores, allowing for longer wavelength shifts.

Until now, NIR-IIa organic fluorophores have been categorized into two groups: (1) fluorophores based on a (donor-acceptor-donor) D-A-D structure and (2) fluorophores based on polymethine structures. The first category comprises fluorophores structured on the (donor-acceptor-donor) D-A-D architecture, where an acceptor unit is strategically nestled between two donor entities. This intricate design, illustrated in Fig. 2A, demands meticulous consideration in selecting electron donors, acceptors, and π -bridging groups.^{50,77} Researchers have created diverse polymer backbones based on the D-A-D framework, utilizing various functional units such as D-A-D, D- π -A-A-D, S-D- π - π -Dn-S (with a π -spacer and S-shielding unit), and D-S-A.⁷⁸ On the other hand, polymethine fluorophores consist of two heterocyclic rings, incorporating heteroatoms like nitrogen, oxygen, or sulfur atoms (Fig. 2B).⁷⁹ One of these heterocyclic rings carries a positive charge and is connected by conjugation with an odd number of carbon atoms. The terminal group of the heterocycle with a positive charge acts as an electron acceptor, whereas the other serves as an electron donor.⁷⁷ Both categories, D-A-D and polymethine, showcase bathochromic shifts in absorption/emission by strategically manipulating their band gap levels. Fig. 3 visually articulates the chemical structures of recently developed small molecules within these categories, alongside semiconducting polymers, while Table 1 provides a concise summary of their photophysical properties. This section predominantly focuses on the intentional design of organic fluorophores exhibiting NIR-IIa emission.

2.1. Molecular engineering of D-A-D based NIR-IIa emissive fluorophores

In the pursuit of developing NIR-IIa fluorophores, we conceptualize their design with a characteristic strong electron donor-acceptor (D-A) configuration. This design choice promotes significant separation between the electron density of the HOMO and the LUMO. A decrease in the energy gap between the HOMO and the LUMO typically leads to a redshifted wavelength. This is accomplished by employing electron acceptor units with strong electron-withdrawing capabilities, thereby lowering the LUMO level.⁵⁰ Additionally, the

incorporation of electron-rich donors with relatively large π -conjugated structures can enhance the intermolecular π - π interactions and facilitate intramolecular charge transfer (ICT).⁹² Besides, the introduction of molecular planarity is also an effective strategy for obtaining increased π -conjugation, thereby augmenting the extent of absorption and emission for the fluorophores.⁸³ It is revealed that the torsional angle between molecular fragments directly affects the planarity of fluorescent dyes, which in turn influences their emission wavelength. There is a direct correlation between the transition wavelength of the first excited state and molecular planarity. Increasing the planarity by reducing the torsional angle leads to a redshift in the emission wavelength due to enhanced orbital overlap and reduced non-radiative decay pathways in planar structures.⁹³⁻⁹⁵ Therefore, understanding the relationship between torsional angle and emission wavelength is crucial for the rational design of fluorescent materials with desired photophysical properties. To illustrate the above phenomenon, we provide examples of various reported fluorophores that emit in the NIR-IIa region based on the D-A-D architecture.

Research involving donor moieties featuring fused ring systems has garnered significant interest because of their rigid, planar structures, which promote intermolecular organization and effective charge transfer. Notably, examples such as 4,8-bis(4-(2-ethylpentyl)thiophen-2-yl)benzo[1,2-*b*:4,5-*b'*]dithiophene (BDT) and 2,5-bis(trimethylstannyl)thieno[3,2-*b*]thiophene (DT) have been investigated. In their respective studies, Fan *et al.* and Dai *et al.* designed unique polymer dots —BDT-TTQ Pdots⁸⁷ (Fig. 4A, i) and PDT-TTQ Pdots⁹¹ (Fig. 4B, i). BDT-TTQ Pdots employed BDT as the donor, while PDT-TTQ Pdots utilized PDT as the donor and 6,7-bis(4-(hexyloxy)phenyl)-4,9-di(thiophen-2-yl)-[1,2,5]thiadiazolo[3,4-*g'*]-quinoxaline (TTQ) as the common acceptor. The BDT-TTQ Pdots demonstrated an absorption peak at 1066 nm and an emission maximum in the NIR-IIa range at 1305 nm as shown in (Fig. 4A, ii), while the PDT-TTQ Pdots showed absorption at 1000 nm with an emission maximum at 1310 nm (Fig. 4B, ii). The incorporation of the planar dual-thiophene unit from the electron releasing DT and the alkylthiophene-substituted benzodithiophene group from the electron donor BDT imparted a more planar structure to the main chain of PDT-TTQ Pdots. Theoretical calculations also reveal that the optimized ground state planar configuration of the molecule maintains small torsional angles of less than 20° along the main chain. This enhanced planarity is expected to expand the absorption range of the polymer, attributed to the enhanced π -conjugation arising from the planar molecular structure. This is reflected in the decreased HOMO-LUMO gaps observed in the Pdots; this is 1.37 eV for PDT-TTQ. Recently, An *et al.* developed T-BBT (Fig. 5B) and BT-BBT (Fig. 5C) Pdots, achieving a planarized molecular conformation by integrating donor units (triarylamine and thiophene) with the cyclopenta-1,3-diene unit attached to the acceptor unit, *m*-benzo[1,2-*c*:4,5-*c'*]bis[1,2,5]thiadiazole (BBT), to form a rigid molecular entity.⁸⁰ This strategic approach not only bolstered the electron-donating





Fig. 3 Chemical structures of molecules emitting in the NIR-IIa region for Pdots.

properties but also elevated the degree of π -conjugation. DFT calculations of the ground state optimised geometry showed that the torsional angle between the donor and acceptor units of both T-BBT and BT-BBT was 0° along the conjugated chain with a completely coplanar conformation. Driven by the strong ICT and extensive π -conjugation in both T-BBT and BT-BBT, they display narrow energy gaps of 1.039 and 1.042 eV, respectively. T-BBT and BT-BBT exhibited distinct absorption peaks at

982 nm and 960 nm, respectively, with emission peaks at 1307 nm and 1246 nm, respectively. T-BBT and BT-BBT exhibited substantial Stokes shifts of 325 nm and 286 nm, respectively, which were indicative of a strong ICT between the donor (D) and acceptor (A). Due to the stronger charge transfer characteristics of T-BBT, it exhibits longer-wavelength absorption and emission maximum peaks compared to those of BT-BBT.



Table 1 Summary of the reported NIR-IIa Pdots

Type	Label	Amphiphilic polymer	$\lambda_{\text{abs}}/\lambda_{\text{em}}$ (nm)	QY (%)	Size (nm)	Ref.
Small molecules	T-BBT	DSPE-mPEG ₂₀₀₀	982/1307 ^a	3.6 ^a	81.5	80
	BT-BBT	DSPE-mPEG ₂₀₀₀	960/1246 ^a	13.5 ^a	70	
	BBTD-1302	DSPE-mPEG ₅₀₀₀	942/1302 ^b	2.4 ^b	80	81
	TTQ-TC-PFru	—	796/1042 ^c , 1100 ^d , 1300 ^c	5.4 ^c , 0.6 ^d	60	82
	B2T	Pluronic-F127	871/1123, 1300 ^d	0.012 ^d	111.4	83
	B2TA	Pluronic-F127	878/1127, 1300 ^d	0.016 ^d	107.8	
	BETA	Pluronic-F127	892/1138, 1300 ^d	0.019 ^d	117.8	
	FD-1080	DMPC	1360/1370 ^e	0.054 ^f	110	84
	FN	Polypeptide PEA	1116/1285 ^b	0.058 ^e	47	85
	HC1342	PEG- <i>b</i> -PCL	1286/1342 ^g	0.015 ^g	32.1	62
	HC1336	PEG- <i>b</i> -PCL	1276/1336 ^g	0.012 ^g	—	
	HC1356	PEG- <i>b</i> -PCL	1288/1356 ^g	0.010 ^g	—	
	HC1362	PEG- <i>b</i> -PCL	1298/1362 ^g	0.011 ^g	—	
	HC1290	PEG- <i>b</i> -PCL	1232/1290 ^g	0.010 ^g	—	
	HC1360	PEG- <i>b</i> -PCL	1290/1360 ^g	0.009 ^g	—	
	HC1366	PEG- <i>b</i> -PCL	1306/1366 ^g	0.010 ^g	—	
	HC1376	PEG- <i>b</i> -PCL	1312/1376 ^g	0.011 ^g	—	
	5H5	PEG/N ₃ -PEG ₈ -cRGD _{fk}	1069/1125, 1300 ^h	2.6 ^g	50	86
Organic semi-conducting polymers	DPQ	DSPE-PEG ₅₀₀₀ -FA	1015/1300 ^c	0.02 ^c	100	63
	BDT-TTQ	Pluronic-F127	1066/1305 ^c	—	100	87
	P1	—	1078/1151 ^d	0.322 ^c	—	88
	P2	—	1080/1151 ^d	0.384 ^c	—	
	P3	DSPE-PEG	1100/1150 1300 ^d	0.505 ^c	182.7	
	P3a	PS-PEG	736/1113, 1284 ^c	0.1 ^d	24	48
	P3b	PS-PEG	759/1115, 1279 ^c	0.6 ^d	14	
	P3c	PS-PEG	746/1123, 1272 ^c	1.7 ^d	16	
	PSQP	DSPE-PEG ₅₀₀₀ -FA	748/1300 ^c	—	172.4	64
	PTQ	DSPE-PEG ₂₀₀₀ -AS1411 liposomes	840/1310 ^c	—	100	89
	TTQ-2TC	PS-PEG	880/1070 1270 ^d	0.3 ^c	140	90
	PDT-TTQ	DSPE-PEG ₅₀₀₀ -COOH	1000/1020, 1310 ^c	—	8	91
	Pttc-SeBTa-NIR1380	CM-PEG-DSPE	1270/1380 ^a	0.25 ^a	73	49

^a Measured in DCM. ^b Measured in DMSO. ^c Measured in THF. ^d Measured in water. ^e Measured in MeOH. ^f Measured in PBS. ^g Measured in DCE.

^h Measured in ACN.

An alternative effective approach for achieving NIR-IIa fluorescence emission in D–A–D structures involves extending the conjugation along the thiophene donor units and diminishing the electron-withdrawing densities. This strategy enhances the charge transfer characteristics. Subsequently, the researchers designed **TTQ-2TC** Pdots (Fig. 4C, i).⁹⁰

In this design, an electron donor is represented by a bithiophene unit with extended alkyl side chains, while TTQ is selected as the acceptor. Notably, these Pdots displayed absorption bands within the range of 600 to 1300 nm, indicative of ICT within the charge transfer states of D–A–D. **TTQ-2TC** displayed a broad absorption at 880 nm and a peak emission maximum at 1270 nm in water as shown in Fig. 4C, ii. Another modification involved altering the donor unit by incorporating structurally twisted donor moieties, specifically (*E*)-1,2-bis(3-tetradecyl-thiophen-2-yl)ethene (TV) and 4,4'-di-*n*-dodecyl-2,2'-bithiophene (2TC), which were further modified with extended alkyl side chains, along with TTQ as the acceptor unit. This alteration led to the formation of **PTQ** Pdots (Fig. 4D, i) capable of exhibiting absorption peaks at 840 nm, with an NIR-IIa fluorescence emission peak at 1300 nm as displayed in (Fig. 4D, ii).⁸⁹ Utilizing diketopyrrolopyrrole (DPP), alternating with an electron rich oligothiophene as the donor and TTQ as the acceptor, Huang's research group developed

DPQ Pdots (Fig. 4E, i).⁶³ DPQ displayed absorption and emission peaks at 1064 nm and 1300 nm, respectively, as shown in Fig. 4E, ii. **BBTD-1302** (Fig. 5) was developed by Ye *et al.*, incorporating electron-rich thiophenes, a styrene moiety, and *N,N*-dimethylamino groups at both ends of the BBT core.⁸¹ Theoretical studies revealed a planar configuration of the two thiophene units consisting of styrene and benzene units. The HOMO of BBTD-1302 spans the entire conjugation skeleton, while the LUMO is located on both the BBT core and the bithiophene units. This indicates an ICT from the donor *N,N*-dimethylamino to the BBT acceptor core, leading to an energy gap of 0.88 eV. BBTD-1302 exhibits a strong absorption and NIR-IIa emission at 942 nm and 1302 nm respectively.

PSQP Pdots (Fig. 6B), incorporating a squaraine acceptor core and 1,4-bis[2-(1-methylpyrrol-2-yl)vinyl]-2,5-didodecyloxybenzene (BP) as the donor unit, exhibit a narrow HOMO–LUMO energy gap. This feature comes from the alternating use of strong donor and acceptor units, leading to longer conjugation in the polymer backbone. The semiconducting polymer PSQP presents a broad absorption at 748 nm and a redshifted emission reaching 1300 nm. In contrast, the small molecular form of the squaraine dye, SQP (Fig. 6A), fails to reach longer wavelengths due to its reduced conjugation compared to that of PSQP Pdots.^{64,98}






Fig. 4 Donor modification for NIR-IIa emission with a TTQ acceptor core; molecular structures and the absorption and emission spectra of D–A–D based semiconducting polymers are as follows: (A) BDT-TTQ, (B) PDT-TTQ, (C) TTQ-2TC, (D) PTQ, (E) DPQ. Adapted with permission from ref. 63 and 89–91 from Elsevier, copyright © 2024, American Chemical Society, copyright © 2020, John Wiley and Sons, copyright © 2021, Elsevier, copyright © 2021 respectively.

2.2. Molecular engineering of polymethine based NIR-IIa emissive fluorophores

Inspired by the structural characteristics of an FDA-approved NIR dye, indocyanine green (ICG), a series of polymethine dyes have been synthesized.⁹⁶ These dyes also possess the unique property of both absorbing and emitting light within the NIR-IIa spectral range. As mentioned earlier, the structures of polymethine fluorophores have long conjugated methine units and two heterocyclic terminals that are either symmetric or asymmetric. Thus, utilizing extended methine units and a terminal unit that is electron-deficient could effectively extend the emission wavelength, resulting in remarkable *in vivo* penetration depth. However, as per the theoretical model, a cyanine with an extremely long chain and long wavelength would lack

a significant gap between the HOMO and LUMO. This difference occurs because the more extended chain means that the terminal group's role becomes insignificant.⁹⁷ Thus, the concept of the “cyanine limit” was introduced, indicating that molecules experienced symmetry disruption beyond a certain length.⁹⁸ In general, elongating the polymethine chain tends to efficiently expand the π -conjugate system thereby reducing the HOMO–LUMO energy gap, which can have NIR-IIa emission. However, most of the polymethine fluorophores reported so far typically have only a maximum of seven methine units. This is attributed to a limitation known as the “cyanine limit”. Conversely, a thoughtful design focusing on heteroatom exchange and introducing donor groups at the heterocyclic terminals has proved to be successful for achieving a bathochromic shift towards longer wavelengths.⁹⁹ Also, the unique





Fig. 5 Donor modification for NIR-IIa emission using the BBT acceptor core with molecular structures of (A) BBTD-1302; (B) T-BBT; and (C) BT-BBT fluorophores with their absorption and emission values.



Fig. 6 Donor modification for NIR-IIa emission using squaraine based acceptors with molecular structures of (A) SQP and (B) PSQP with their absorption and emission values.

chain structure and planarity of the heterocyclic terminals make polymethine fluorophores susceptible to a specific aggregation phenomenon in water, resulting in the formation of J-aggregates causing notable changes in the optical properties.⁷² These highly organized assemblies of organic dyes, compared to monomer molecules, exhibit spectroscopic characteristics such as bathochromically shifted absorption and emission, minimal Stokes shifts, and enhanced absorption coefficients, all achieved through self-assembly processes.^{72,100} Following this, we elaborate on the specific approach to extending wavelengths based on the principles outlined above.

(i) Modifying the conjugation system of polymethines

(a) *Increasing the length of the conjugated chain.* Extension of the polymethine conjugated chain predominantly involves increasing the number of methine units within the elongated

chain. Our research team has successfully synthesized three polymethine dyes, namely NIR1125, NIR1270, and NIR1380 (Fig. 7).⁷⁷ These dyes are characterized by a narrow-band feature achieved through expansion of the conjugation length using intermediate methine units. NIR1125 comprises three methine units, NIR1270 consists of five methine units, and NIR1380 incorporates seven methine units, each linked to thiopyrylium (an electron-releasing group) and thiopyrylium salt (an electron-withdrawing unit) at the terminals, as illustrated in Fig. 7A–C. As the number of methine units increased from three to seven, it resulted in a reduction in the HOMO–LUMO energy gap, as represented in Fig. 7D. The HOMO–LUMO gaps were measured for each dye individually: NIR1125 exhibited a gap of 1.59 eV, NIR1270 showed a reduced gap of 1.46 eV, and NIR1380 demonstrated the smallest gap of 1.36 eV. As a result, the reduction in the energy






Fig. 7 Enhancing the conjugation length to achieve NIR-IIa emission. Molecular structures of polymethine-based fluorophores (A) NIR1125, (B) NIR1270, and (C) NIR1380. (D) Computed HOMOs and LUMOs of the molecular fluorophores. (E) Absorption spectra in DCM: NIR1125, NIR1270, and NIR1380 shown as red, blue and green lines respectively. (F) Emission spectra in DCM: NIR1125, NIR1270, and NIR1380 shown as red, blue, and green lines respectively. Reproduced with permission from ref. 77 from John Wiley and Sons, Copyright © 2020. (G) Structures of NIR1270 and HC1342 showing redshifted NIR-IIa emission by introducing a rigid ring into the conjugated chain.

gap led to shifts towards longer wavelengths in both absorption and emission. NIR1125 displayed absorption and emission peaks at 1066 nm and 1125 nm, respectively. In the case of NIR1270, absorption and emission peaks are observed at 1188 nm and 1270 nm, respectively. Notably, the dye with seven methine units, NIR1380, exhibited absorption and NIR-IIa emission peaks at 1270 nm and 1380 nm as displayed in Fig. 7E and F. This sequential exploration of polymethine dyes with increasing methine units not only provided insights into their electronic structure but also demonstrated a systematic decrease in the energy gap, which enabled extension of the wavelengths into the NIR-IIa region.

(b) *Introducing rigid rings into the conjugated chain.* Despite the effectiveness of increasing the number of methine units to extend the emission wavelength in polymethines, the “cyanine limit” phenomenon poses challenges to the stable synthesis of longer-emitting fluorophores. Consequently, many researchers have sought to improve the fluorophore emission wavelengths by altering the chain structures while maintaining a consistent number of methine units. The predominant approach involves inserting a set of rigid rings into the central portion of the methine chain. Introducing a rigid ring into the methine unit helps to maintain a planar structure, which is crucial for efficient π -conjugation and leads to a longer emission wavelength due to the extended conjugation pathway. For example,

as depicted in Fig. 7G, the introduction of a five-membered ring containing a nucleofugal chlorine group into the central chain bridge of NIR1270 dye resulted in a bathochromic shift of around 72 nm, producing HC1342 dye.^{62,77}

(c) *Extending the conjugation of the terminal moiety.* An alternative strategy to attain longer wavelengths might involve extending the conjugated system on the terminal moieties. Studies have revealed that introducing fused conjugated structures on the terminal moieties can lead to a redshifted emission.¹⁰¹ However, this tactic has not yet been reported to create polymethine dyes with emission maxima in the NIR-IIa region.

(ii) **Tuning donor and acceptor moieties.** The key factor affecting the optical properties of polymethine dyes is the terminal group. Effective methods for extending the emission wavelength of polymethine fluorophores is to replace the heteroatom in the end groups and/or add a donor group to the end heterocyclic unit. This approach enhances the density of its electron cloud, contributing to wavelength extension. To

illustrate, Fan *et al.* undertook a systematic engineering effort to develop a series of heptamethine cyanines (HCs) characterized by NIR-IIa emission. The study involved the design of nine heptamethine cyanines, namely HC1222, HC1342, HC1336, HC1356, HC1362, HC1290, HC1360, HC1366, and HC1376, with meticulous attention to structure–property relationships⁶² (Fig. 8A–D). Firstly, all the fluorophores in this series were constructed with a heptamethine system featuring a 5-membered bridge. This structural characteristic set the stage for the desired NIR-IIa emission. The second design consideration involved the incorporation of the 4,6-diphenyl-substituted α -pyrrocyanine moiety. A third design element involved changing the heteroatom (X) in the α -thiopyrrocyanine moiety from oxygen (O) to sulfur (S). These modifications contributed significantly to achieving a notable redshift in the emission, aligning with the target NIR-IIa region. Lastly, two phenyl groups were introduced to realize substituent effects. This enabled the precise tuning of




Fig. 8 Tuning the donor and acceptor moieties of polymethine based HC fluorophores (A–D) for NIR-IIa emission.



the spectral properties of the heptamethine cyanines, ultimately resulting in the desired NIR-IIa emission. HC1222 shows absorption at 1180 nm and emission at 1222 nm, with an energy gap of 1.409 eV. Heteroatom exchange from O to S in the α -thiopyrrocyanine scaffold of HC1222 resulted in HC1342. This strategy of atom exchange led to a decrease in the energy gap to 1.321 eV, causing a bathochromic shift in the absorption and NIR-IIa emission at 1286 nm and 1342 nm, respectively. The phenyl groups located at positions 6 and 4 in the heterocyclic terminals of HC1342 undergo substitution with a methoxy group at the *meta* position to yield HC1356 and HC1360, at the *para* position to yield HC1362 and HC1366, and at the *ortho* position to yield HC1290 and HC1336. The energy gap is determined to be 1.316 eV for both HC1356 and HC1360. In contrast, the energy gap for HC1362 and HC1366 is measured to be 1.298 eV. As a result, there was a shift towards longer wavelengths in NIR-IIa emission caused by a reduced energy gap compared to HC1342. The energy gap is found to be 1.332 eV for both HC1290 and HC1336; this is blueshifted when compared to HC1342, which can be attributed to an enhanced steric effect. By substituting *p*-methoxy groups on both phenyl rings of HC1342, the resulting HC1376 exhibits the smallest energy gap of 1.275 eV. This results in an emission shifted towards the NIR-IIa region compared to all other HCs. Thus, HC1336, HC1356, HC1362, HC1290, HC1360, HC1366, and HC1376 exhibit absorption peaks at 1276, 1288, 1298, 1232, 1290, 1306, and 1312 nm and emission peaks at 1336, 1356, 1362, 1290, 1360, 1366, and 1376 nm respectively.

(iii) J-Aggregates for redshifted emission in cyanine dyes.

Over 80 years ago, independently discovered by Scheibe and Jelley, the J-aggregates of organic dyes, exemplified by 1,10-diethyl-2,20-cyanine chloride, marked the beginning of a significant exploration.^{72,102} Subsequently, various self-assemblies with similar characteristics emerged. These aggregates, often referred to as Scheibe aggregates or J-aggregates, display narrow and shifted absorption/emission bands towards longer wavelengths, a minimal Stokes shift, and increased ϵ .^{77,103,104} The fluorescence displayed by J-aggregates is a result of the dyes aggregating together; this was observed by Tang's group in 2001 and found to be related to the aggregation-induced emission (AIE).¹⁰⁵ Unlike AIE, where fluorescence is triggered by intramolecular rigidification, J-aggregates usually show new fluorescence bands because of intermolecular interactions.¹⁰⁶ The alignment of transition dipole moments in J-aggregates is a key factor contributing to their unique optical properties. This arrangement, achieved by positioning molecules 'head-to-tail' or in a 'shifted plates' configuration, leads to a beneficial coupling of the transition dipoles in the excited state.¹⁰⁷ In J-aggregates, the dyes absorbing and emitting in the NIR window have attracted significant attention for biomedical imaging.¹⁰⁸ In the late 1930s, researchers made systematic changes to the structure of cyanine dyes, revealing the important features that lead to J-aggregation. It is found that the longer conjugated structure of cyanine dye forms more stable aggregates compared to traditional dyes. Over time, numerous cyanine dyes with J-aggregation in the NIR range have been

synthesized, and researchers have extensively studied how their optical properties relate to changes in structure. This discussion primarily centres on NIR-IIa-emitting J-aggregates, exploring their significance in the context of biomedical imaging within the advantageous NIR-IIa region.

J-Aggregates are characterized by a redshifted emission compared to the monomeric form of the dye. This redshift is attributed to the strong intermolecular interactions between the planar dye molecules in the aggregate state.⁷² A notable illustration comes from Zhang's research team, who demonstrated how the amphiphilic cyanine dye FD-1080 could self-assemble with 1,2-dimyristoyl-*sn*-glycero-3-phosphocholine (DMPC) to form a stable FD-1080 J-aggregate, as seen in Fig. 9A, i.⁸⁴ This aggregate displays unique absorption and emission peaks at 1360 nm and 1370 nm respectively, both falling within the NIR-IIa region as seen in Fig. 9A, ii. These values show a significant bathochromic shift compared to its monomeric form, FD-1080, which absorbs and emits light at 1046 nm and 1080 nm, respectively. Another interesting example involves the work of Teng *et al.*, who designed a bromine- and piperazine-modified cyanine dye called FN, and incorporated it into nanomicelles through encapsulation with an amphiphilic polypeptide featuring tertiary amine side chains (PEA), leading to the development of J-aggregates as represented in Fig. 9B, i.⁸⁵ FN and PEA self-assemble to form P@FN9 J-aggregates characterized by an absorption peak at 1116 nm and show NIR-IIa fluorescence, reaching a peak at 1285 nm as displayed in Fig. 9B, ii and iii. These examples showcase the potential of tailored self-assembly processes for achieving unique and advantageous spectroscopic features in the development of advanced contrast agents.

3. Molecular design of organic fluorophores to enhance NIR-IIa brightness

Fluorescence imaging in the NIR-IIa region offers advantages such as reduced tissue scattering and diminished autofluorescence. Consequently, the role of probe brightness becomes pivotal in enhancing the signal-to-background ratio for fluorescence-related bio-applications. A key consideration for an optimal fluorophore lies in its ability to exhibit robust absorption and emission characteristics upon exposure to light. In this context, both D-A-D and polymethine fluorophores share a common feature—an extensively bulky conjugated system, accompanied by a narrow HOMO/LUMO energy gap. Unfortunately, this characteristic often results in a low QY. The fluorescence QY of NIR-II fluorophores is typically low because of limitations imposed by the energy gap law and the significant quenching behavior caused by aggregation due to highly conjugated structures, known as aggregation-caused quenching (ACQ) behavior.¹⁰⁹ Despite this limitation, the design of NIR-IIa organic probes requires a broader perspective beyond wavelength considerations alone. Fluorescence brightness





Fig. 9 (A) (i) Formation of J-aggregates using the polymethine fluorophore FD1080 with DMPC; (ii) absorption spectra of the monomer and J-aggregates of FD-1080, illustrating absorption and emission with solid and dashed lines respectively. (B) (i) Formation of J-aggregates using the polymethine fluorophore FN with PEA; (ii) absorption spectra of the corresponding J-aggregates of FN at various molar ratios of PEA/FN; (iii) FN and its J-aggregates showing emission spectra at different PEA/FN molar ratios. Adapted with permission from ref. 84 and 85 from American Chemical Society, copyright © 2019 and Elsevier, copyright © 2022 respectively.

emerges as a more critical factor for bioimaging. Achieving optimal fluorescence brightness in fluorophores is a nuanced challenge influenced by two important factors: the molar extinction coefficient ϵ and fluorescence QY. Fluorescence brightness is not solely contingent on either the fluorescence QY or ϵ ; rather, it is an outcome determined by the product of both factors. Hence, these parameters are intricately linked, creating a delicate balance in their optimization. Notably, the quest for a higher QY can be counteracted by a decrease in ϵ . This makes it challenging to boost both features at the same time.⁷⁸ Until now, scientists have devised diverse approaches to address the challenge of enhancing the brightness of D-A-D and polymethine-based fluorophores. This involves implementing chemical modifications to the molecular backbones of the fluorophores, which are discussed elaborately in subsequent sections.

3.1. Chemical modification of D-A-D based fluorophores to improve brightness

In the case of D-A-D fluorophores, researchers have identified that incorporating hydrophobic donors, incorporating long

alkyl chains to donor units, or introducing shielding units to the molecular backbone prove to be an effective strategy to reduce intermolecular π - π stacking, hence reducing the ACQ that helps to suppress non-radiative decay processes, ultimately enhancing fluorescence properties.⁶⁹ Additionally, the integration of AIE moieties has proved to be a successful approach for achieving high QYs for D-A-D fluorophores.³³ Furthermore, introducing alternating planar and twisted molecular structures into fluorophore design has demonstrated the ability to yield high QYs and high ϵ .¹¹⁰

Fan *et al.* introduced three distinct polymer backbones with a D-A-D structure, where each of them featured varying bulky side units. These polymers include thiadiazoloquinoline (TQL) and BDT as the acceptor and donor units. The donor unit is modified with different alkyl side chains to enhance the QY of the Pdts. This led to the development of **P1**, **P2**, and **P3**, corresponding to the introduction of linear, short, and bulky-branched side chains, respectively, as shown in Fig. 10A-C.⁸⁸ To understand the structural differences, density-functional theory (DFT) was used. It showed that **P3**,



with bulky branched side units, had the largest angle between the BDT donor and TQL acceptor units. This observation indicates a more pronounced distortion in the polymer backbone compared to P2 and P1. Consequently, P3 showcased a notable anti-ACQ effect, contributing to a higher QY. The fluorescence QYs were determined to be 0.322% for P1, 0.384% for P2, and 0.505% for P3, highlighting the impact of different side units that affected the optical characteristics of these polymers.

Wu's group utilized phenothiazine as the donor, driven by the exceptional electron-donating capabilities of sulfur and nitrogen atoms within phenothiazine. The incorporation of various side groups onto phenothiazine units imparts a non-planar structure, effectively impeding π - π molecular stacking. To enhance the polymer's properties, they incorporated a robust acceptor, benzobisthiadiazole (BBT), resulting in the formation of three conjugated polymers (P3a, P3b, and P3c) (Fig. 10D and E) with NIR-IIa emission.⁴⁸ They introduce AIE and anti-ACQ characteristics within a single molecular entity. The AIE characteristics originate from the phenothiazine donor, limiting non-radiative decay pathways in the aggregated state. Concurrently, the introduction of the anti-ACQ feature through side group modifications of phenothiazine experiences steric hindrance due to the presence of bulky side substituents, which in turn weakens π - π stacking. Among these polymers, P3c Pdots stand out, due to the bulky structure of diphenylanthracene, which ameliorates the anti-ACQ effect.

Consequently, the QYs for P3a, P3b, and P3c Pdots were measured to be 0.1%, 0.6%, and 1.7%, respectively. Notably, P3c Pdots exhibit a fluorescence brightness roughly 21 times greater than that of P3a Pdots, highlighting the significant impact of side group modifications on the optical performance of these polymers.

As previously discussed, a fluorophore's brightness relies on both the QY and ϵ collectively. Fan's research group introduced an innovative approach to significantly augment the NIR-IIa fluorophores' brightness by combining two distinct properties: (1) structural planarization to enhance ϵ and (2) a twisting configuration to boost QY within a single fluorophore. In this work, alkyl thiophenes and BBT functioned as the donor and acceptor units. Three molecules were meticulously designed, namely, B2T, B2TA, and BETA (Fig. 11A-C).⁸³ The approach involved incorporating three thiophene units for B2T and introducing a nonconjugated alkyl side chain into the terminal thiophene of B2T to create B2TA. DFT calculations unveiled that the addition of a terminal nonconjugated alkyl unit resulted in a more planar structure for B2TA compared to B2T. Consequently, B2TA exhibited a higher absorption coefficient (ϵ) of $7.38 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$ with a QY of 0.016%, while B2T displayed a lower ϵ of $3.18 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$ with a QY of 0.013%. To achieve a strong absorption while preserving the fluorophore's high QY, a bulky planar 3,4-ethoxylendioxythiophene (EDOT) unit is introduced by replacing a thiophene unit



Fig. 10 D-A-D based molecular structures of (A-F) P1, P2, P3, P3a, P3b, and P3c Pdots for high QY.





Fig. 11 D–A–D based fluorophores (A–E) with planar and twisted molecular architectures for high QY and high ϵ .

near the terminus of B2T, resulting in BETA. This led to enhanced planarity, displaying an increased ϵ of $11.3 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$ with a QY of 0.019%, surpassing both B2T and B2TA. DFT calculations revealed that the terminal alkyl chain and bulky EDOT replacement contributed to increased molecular planarity for the fluorophore. In their research, Cai *et al.* introduced two fluorophores, T-BBT and BT-BBT (Fig. 11D and E), characterized by a structurally rigid and planar conformation.⁸⁰ These fluorophore molecules feature BBT as the acceptor core, with the donor unit comprising thiophene and triphenylamine fused with cyclopenta-1,3-diene. Both T-BBT and BT-BBT have conjugated backbones that adopt a completely coplanar structure, as revealed by DFT calculations. This structural rigidity reduces non-radiative decay pathways related to electronic vibration coupling. This conformational planarization resulted in notably high ϵ values for both T-BBT and BT-BBT of $43.9 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$ and $45.5 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$, respectively. Simultaneously, the structural rigidity contributed to a high QY of 3.6% for T-BBT and an even more substantial QY of 13.5% for BT-BBT. The study underscores how the strategic design of fluorophores with rigid, planar conformations can effectively enhance both their absorption properties and fluorescence efficiency. By employing these strategic methods, it is possible to simultaneously achieve high values of both ϵ and QY in the resulting fluorophores.

3.2. Improving brightness in polymethine based NIR-IIa fluorophores

To enhance the QY of polymethine fluorophores, various strategies have been introduced.⁷⁷ These include interactions with biomolecules thereby reducing nonradiative processes, imposing conformational constraint, and diminishing intersystem crossing by altering the presence of heavy atoms.^{111,112} Other ways to increase the brightness of polymethine dyes involve minimizing aggregation effects to maintain a molecular monomeric state, ensuring efficient absorption and emission capabilities.^{113,114}

The diminished fluorescent brightness observed in NIR-II polymethine fluorophores within biological systems is primarily attributed to ACQ, a common phenomenon. This phenomenon may arise due to the extended π -conjugation of the methine units and/or terminal heterocycle moieties, essential for achieving redshifted absorption and emission wavelengths.^{77,79} However, this extension unavoidably accelerates molecular self-aggregation by means of solvatochromism and π -stacking, leading to loss of symmetry, broader absorption spectra, and decreased brightness in aqueous solutions. As a practical strategy to mitigate these effects and enhance fluorophore brightness, introducing a bulky group that induces steric hindrance proves effective.⁷⁷ To illustrate,





Fig. 12 Enhancing the NIR-IIa brightness of polymethine based fluorophore HC1342 by introducing steric hindrance from smaller and bulky counter-ions.

Zhang's team engineered a series of heptamethine cyanine (HC) dyes, enabling precise adjustments of maximal absorption/emission wavelengths within the 1100 to 1400 nm range.⁷⁷ Among the polymethine HCs shown in Fig. 8A–D, **HC1342** displayed a QY of 0.015% with absorption and NIR-IIa emission peaks at 1286 nm and 1342 nm, respectively. However, when introduced into aqueous environments, HC1342 displayed reduced brightness due to the ACQ phenomenon as a result of molecular self-aggregation. To address this, one practical approach involves introducing a bulky group that induces steric hindrance. Validating this concept, HC1342 demonstrated a remarkable 13-fold increase in fluorescent brightness upon introduction into an aqueous solution, achieved through exchanging counterions for the bulky tetrakis(pentafluorophenyl) borate (F_5 -TPB), resulting in a QY of 0.004% and ϵ of $46\,560 \text{ M}^{-1} \text{ cm}^{-1}$. This contrasted with its original form paired with the smaller BF_4 counter-ion, which had a QY of 0.002% and ϵ of $6800 \text{ M}^{-1} \text{ cm}^{-1}$, while maintaining similar absorption and emission profiles within the NIR-IIa range (Fig. 12).

4. Applications of NIR-IIa fluorescent Pdots for deep-tissue imaging

Effective deep-tissue imaging relies mainly on both excitation and emission photons traversing through biological tissues, encountering a variety of interactions that profoundly impact imaging depth. These interactions encompass reflection occurring at the surface interface, scattering within the bio-tissues, absorption, and autofluorescence from biological species, all of which are depicted in Fig. 1.¹¹⁵ As we delve deeper, it becomes evident that the success of deep-tissue imaging hinges on navigating through these intricate processes. Fortunately, these factors are highly diminished as we move towards longer wavelengths. In recent years, there has been

notable rise in multidisciplinary research focused on the advancement of organic fluorophores tailored for non-invasive imaging within the second near-infrared window (NIR-II, 1000–1700 nm).^{32,116} Consequently, the advantageous features of the NIR-IIa window, characterized by longer wavelengths (1300–1400 nm), can lead to reduced photon scattering. Additionally, there is a significant decrease in autofluorescence compared to the broader NIR-II range.³⁵ This specific NIR-IIa wavelength range enables deep tissue imaging in living subjects, offering promising prospects for biomedical research and clinical uses. The combined benefits of reduced scattering and autofluorescence render NIR-IIa imaging highly proficient for achieving high-resolution and deep-tissue imaging.³⁵

In this scenario, various NIR-IIa emitting organic fluorophores have been developed and applied in deep-tissue fluorescence imaging. For *in vivo* deep tissue imaging purposes, conjugated polymers or organic dyes are embedded within an amphiphilic polymer matrix such as polyethylene glycol (PEG) segments, resulting in the formation of Pdots.¹¹⁷ The Pdots exhibit enhanced brightness and photostability due to the high concentration of fluorophores per particle, which are safeguarded by their surrounding polymer embedded matrix.^{117,118} Additionally, the presence of PEG segments on the Pdots serves to minimize nonspecific adsorption on blood proteins while extending the *in vivo* blood circulation time, thereby preventing rapid renal or hepatic clearance.^{15,33,119,120} When utilizing clinically approved agents like ICG^{121,122} and methylene blue (MB),¹²³ extensively explored for deep tissue imaging applications, they exhibit short retention periods due to rapid clearance allowing for repeated administration. However, the scarcity of NIR-IIa emissive dyes has prevented the full exploration of the desired window for deep-tissue imaging. In this context, our attention in this section is predominantly centered on the exploration of deep-tissue imaging facilitated by NIR-IIa Pdots comprised of small molecules and semiconducting polymers. This review primarily focuses on



utilizing NIR-IIa fluorescence imaging to achieve high-resolution visualization of diverse vascular components, encompassing those throughout the entire body, brain, hind limb, and abdomen, and for targeted tumor imaging, drawing upon findings from various research studies.

4.1. *In vivo* NIR-IIa fluorescence imaging of the vasculature system

The vascular system plays crucial roles in maintaining normal adult physiology and can worsen diseases by being involved in inflammation and aiding the growth and spread of cancer.¹²⁴ It responds to various stimuli such as vascular endothelial growth factor A (VEGFA) by undergoing alterations in diameter, permeability, and blood flow.¹²⁵ In this context, NIR-IIa fluorescence imaging can visualize blood vessels with exceptional contrast and resolution, enabling the observation of minute capillaries and the identification of subtle alterations in vascular structure. Moreover, it facilitates the real-time monitoring of blood flow and perfusion, thereby serving as a valuable tool for investigating both normal vascular physiology and pathological conditions.^{126,127} The SBR holds significant importance in vascular imaging as it directly impacts the quality and precision of acquired images. In the context of NIR fluorescence imaging, longer wavelengths in the NIR-II region can contribute to a higher SBR compared to the blurry NIR-I region. This improved SBR in the NIR-II region enables higher spatial resolution, deeper tissue penetration, and enhanced contrast, all essential for identifying deep lesions with high contrast.¹²⁸ The newly introduced NIR-IIa window fluorophores have garnered significant interest for their potential in non-invasive *in vivo* imaging at longer wavelengths, attributed to their superior resolution and SBR.^{129,130} For example, our research group developed **Pttc-SeBTa-NIR1125** Pdots and **Pttc-SeBTa-NIR1380** Pdots for NIR-IIa vascular imaging in mice.⁴⁹ These Pdots were synthesized by chemically bonding NIR dyes (NIR1125 and NIR1380) to a large semiconducting polymer (Pttc-SeBTa-PFCOOH), chosen for its anti-ACQ properties. This property particularly arises from the structural rigidity exhibited by the Pttc monomer, along with the steric effects offered by the SeBTa monomer. Subsequently, modifying the fluorene unit of the polymer skeleton with an azide functional group enables it to further react with the NIR dye molecules, resulting in the desired polymers. These polymers were then encapsulated into CM-PEG-DSPE to form nanoparticles (Fig. 13A and B). The Pdots demonstrated narrow absorption and emission bands ideal for NIR-IIa fluorescence imaging, which could potentially enhance penetration depth and result in a higher SBR (Fig. 13C). Compared with long-pass filters (LPFs) of different wavelengths, as shown in Fig. 13D, it is observed that longer wavelengths, despite yielding lower fluorescence emission, provide improved spatial resolution and SBR by minimizing background interference. Using a 1250 nm LPF, we observed a significantly higher SBR *in vivo* for Pttc-SeBTa-NIR1380 Pdots compared to Pttc-SeBTa-NIR1125 Pdots (Fig. 13E). This enhancement in SBR facilitated clearer visualization of blood vessels all over the mouse body (Fig. 13E), par-

ticularly evident in the hind limb and spinal cord regions, demonstrating the efficacy of longer wavelengths for achieving high-quality *in vivo* imaging with improved SBR (Fig. 13F and G). The *in vivo* imaging of the mouse brain vessels also demonstrated outstanding SBRs (Fig. 13H).

In another example, Fan's research group developed PDots based on a telechelic glycopolymer that is water soluble called TTQ-TC-PFru Pdots, which could emit in the NIR-IIa region based on the D-A-D structure (Fig. 14A).⁸² Upon intravenous injection of these Pdots, real-time imaging was conducted using excitation at 808 nm with varying LPFs. Higher SBRs were observed in images obtained with the 1300–1400 nm LPF compared to those obtained with the 1000–1100 nm LPF, indicating superior clarity in the images of the mouse hind limb, brain, and belly vessels (Fig. 14B, (i)–(vi)). This underscores the efficacy of longer wavelengths at improving image quality, including contrast, and penetration depth for *in vivo* imaging.

Elevating the SBR in fluorescence imaging has been a central area of investigation, with a focus on advancing novel fluorophores characterized by increased brightness.⁸³ As previously discussed, Fan *et al.* devised highly luminous BETA nanoparticles (NPs) by incorporating planar and twisted molecular entities within the same molecular structure.⁸³ Their findings revealed blood vessels of the brain and leg with amplified SBRs in the NIR-IIa window compared to the NIR-II region by utilizing laser excitation at 1064 nm and 808 nm, respectively as shown in Fig. 15A and D. The exceptional fluorescence brightness of BETA NPs also ensures a superior SBR when compared to its counterpart, B2TA NPs (Fig. 15B, C, E and F). Similarly, the highly bright HC1342/F₅-TPB NPs, utilizing polymethine dye counter-ion pairing, produced sharp vascular images. In the mouse brain, hind limb, back, and abdomen, peak SBRs of 4.34, 4.42, 3.78, and 3.20 were attained, respectively, using a 1319 nm LPF (Fig. 15G, H, K, and L). Six tiny vessels in the back were clearly distinguished, with individual full widths at half-maximum (FWHMs) ranging from 183 to 297 μm (Fig. 15I, J, M, and N). These findings underscored the efficacy of the counter-ion-paired strategy at enhancing imaging performance through heightened brightness and elevated SBRs.

However, the limited duration of blood circulation poses challenges for the continuous monitoring of dynamic physical processes.¹³¹ Addressing this concern, Zhang's team modified the surfaces of P3a and P3c Pdots with PS-PEG to prolong the blood circulation time.⁴⁸ Employing PEGylated Pdots, the mouse body was subjected to NIR-IIa imaging (Fig. 16A). Remarkably, images acquired with P3a Pdots are nearly undetectable, whereas P3c Pdots, with both AIE and anti-ACQ effects, exhibit a high SBR (Fig. 16B–D). PEGylated P3c Pdots were subsequently utilized for NIR-IIa imaging of the cerebral vasculature of the mouse. Using a LPF with a wavelength of 1319 nm (NIR-IIa) for fluorescence imaging resulted in notably sharper images with a higher SBR value than those obtained with a NIR-II LPF with a wavelength of 1250 nm (Fig. 16E–G). The high SBR remained relatively stable over 180 min due to





Fig. 13 (A) Synthesis scheme for Pttc-SeBTa-NIR1125/1380 semiconducting polymers. (B) Schematic for the preparation of Pttc-SeBTa-NIR1126/1380 Pdts. (C) Absorption and emission spectra represented as solid and dashed lines, respectively, corresponding to Pttc-SeBTa-NIR1125, Pttc-SeBTa-NIR1380 and Pttc-SeBTa-NIR1270 Pdts in water shown as red, blue and green lines, respectively. (D) Images shown under ambient light (first row) of Pttc-SeBTa-NIR1125 and Pttc-SeBTa-NIR1380 Pdts (left and right) with LPFs at 1020 nm, 1100 nm, 1250 nm, and 1312 nm (bottom rows) under 808 nm laser excitation. (E) Whole-body imaging of mice post intravenous administration of Pttc-SeBTa-NIR1125/1380 Pdts imaged with different LPFs with wavelengths of 1100 nm and 1250 nm, respectively, in supine and prone positions shown in left and right images. (F) Enlarged images of mouse hind limb vasculature highlighted in the green squares of (E, i) and (E, ii) (top and bottom row, left), with green lines showing their respective cross-sectional intensity profiles in (F) for Pttc-SeBTa-NIR1125 (left)/1380 (right). (G) Expanded view of the area in the red squares marked on the spinal cord of (E, i) (top row, right) and (E, ii) (bottom row, right), with the red lines showing their respective cross-sectional intensity profiles for Pttc-SeBTa-NIR1125/1380 Pdts (right). (H) Wild-type C57BL/6 mouse brain vasculature NIR-II fluorescence imaging post-intravenous injection of Pttc-SeBTa-NIR1125/1380 Pdts displayed in top and bottom images using 1100 nm and 1250 nm LPF. Adapted with permission from ref. 49, from John Wiley and Sons, copyright © 2020.

the extended circulation half-life (approximately 6.6 h) of the PEGylated Pdts. In contrast, ICG is a small molecule dye typically cleared within about 5 min, resulting in a very brief imaging window.¹³²

4.2. *In vivo* NIR-IIa fluorescence imaging of tumors

Cancer poses a significant public health challenge, with alarming statistics indicating nearly 10 million deaths recorded in 2020. Timely detection and treatment are essential for reducing this mortality rate.^{133,134} In this context, harnessing the unique technical features of NIR-IIa fluorescence imaging, through the utilization of NIR-IIa Pdts, demonstrates significant promise for effectively guiding image-guided surgical tumor navigation with a high SBR.¹¹⁷ A robust SBR enables the reliable detection and assessment of tumors with high contrast and highly diminished background, providing valuable insights for surgical decision-making and improving cancer prognosis.¹³⁵ Despite Pdts demonstrating effective resolution for imaging the vascular system as discussed in the previous section, it is crucial to note that the experimental conditions

differ significantly in the case of tumor targeting from those employed in vascular imaging.

It is essential to first understand the impact of delivery on the effectiveness of nanoparticles (NPs) for tumor-targeting purposes.¹³⁶ Following a fundamental principle known as the “enhanced permeability and retention” (EPR) effect, nanoparticles traverse through openings between endothelial cells, known as inter-endothelial gaps.¹³⁷ These gaps vary in size distribution, typically ranging from 100 to 500 nm, depending on the type and stage of the tumor, as observed in mouse models. This leads to a higher delivery efficiency and tumor accumulation in nanoparticles with hydrodynamic diameters below 100 nm compared to larger particles.¹³⁸ Secondly, to prolong the circulation time of nanoparticles *in vivo*, researchers commonly coat the fluorophores with neutral polymers, such as PEG.¹²⁶ A longer circulation time enhances the likelihood of nanoparticles accumulating in tumors. The blood half-life of nanoparticles directly correlates with the length and density of PEG ligands.^{126,131,139} Hence, considering the aforementioned factors, various research groups have developed nanoparticles




Fig. 14 (A) Illustration depicting the formation of TTQ-TC-PFru Pdots. (B) TTQ-TC-PFru Pdots after injection into mice for NIR-IIa imaging of (i) hind limb, (ii) brain, and (iii) belly vessels using different LPFs (spanning from 1000 to 1400 nm) under 808 nm laser excitation (exposure time = 200 ms). Circles in red denote regions as a reference for background noise. (iv, v, vi) SBR values obtained from the marked regions of red dotted lines in the cross-sectional profiles of fluorescence intensity obtained with different LPFs. Reproduced with permission from ref. 82. Copyright © 2020, American Chemical Society.

incorporating NIR-IIa fluorophores tailored for bioimaging applications in the NIR-IIa window, ensuring efficient delivery to solid tumors *in vivo*.

In the work done by Ding *et al.*, the polymethine thiopyrylium dye, known as 5H5, exhibited absorption and emission characteristics within the NIR-II window, showcasing absorption and emission peaks at 1069 nm and 1125 nm, respectively.⁸⁶ Additionally, it presents an off-peak shoulder emission in the NIR-IIa window. The process of preparing 5H5 NPs involves coating them with PEG, leading to an extended blood circulation time for the PEG-modified NPs (Fig. 17A). The 5H5 NPs were injected into mice bearing U87MG tumors and a non-invasive examination of tumor vascular structures for NIR-II imaging was conducted using 808 nm and 1064 nm excitation sources. The 5H5 NPs with a hydrodynamic size smaller than 100 nm facilitates clear visualization of both tumorous microvasculature (Fig. 17B) and tumor tissues (Fig. 17C); this is attributed to tumor-selective targeted NIR-II and NIR-IIa imaging based on the EPR effect. Additionally, some fluorophores may not proficiently target tumors, necessitating the connection of a targeted molecule to enhance tumor resolution. Therefore, to enhance both tumor targetability and

make the dye water soluble, the 5H5 fluorophore with a terminal alkyne group is covalently conjugated to the peptide c(RGD)_{nk}. The highest tumor contrast, yielding a tumor tissue to non-tumor tissue (T/NT) value of 4.0, is obtained under 808 nm laser irradiation. The T/NT value increased to 6.8 under 1064 nm excitation for 8 h (Fig. 17D and E). An *ex vivo* biodistribution analysis conducted after 24 h revealed the accumulation of NPs in the liver and spleen when employing the 1064 nm laser, implying that the biliary system primarily facilitated clearance (Fig. 17F and G).

In another example, Teng *et al.* employed a self-assembly approach involving the polymethine dye FN and the amphiphilic polypeptide PEA to create J-aggregates using P@FN9 NPs, aiming for precise NIR-IIa tumor imaging.⁸⁵ Motivated by the superior NIR-IIa imaging capabilities observed in the mouse vasculature compared to NIR-II imaging, as depicted in Fig. 18A–C, the researchers conducted experiments to assess the fluorescence performance in tumor imaging. The fluorescence images of tumors in Fig. 18D show a steady rise in signal over time, attributed to the EPR effect. The T/NT fluorescence ratio demonstrated a notable increase, as shown in Fig. 18E, reaching 9.2 within 24 h post-injection, highlighting






Fig. 15 NIR-IIa fluorescence imaging of (A) brain and (D) leg vessels in the following groups: B2TA NPs under 1064 nm shown at the top with 3000 ms of exposure time, BETA NPs under 1064 nm and 808 nm laser shown in the middle and bottom with 3000 ms and 500 ms exposure times respectively. The scale bar denotes 5 mm. (B and E) Cross-sectional profiles of intensity indicated by the red lines in panels (A) and (D) (top and middle) to compare the fluorescence intensity of vessels across different groups. (C and F) Cross-sectional profile intensity indicated by the red lines in panels (A) and (D) (middle and bottom) to compare imaging quality under different laser excitation. Error bars are represented as mean \pm standard deviation for $n = 3$. (G, K, H, L) NIR-II imaging of mouse brain (G), backside (K), hind limb (H), and abdomen (L) vasculature following injection with HC1342/F₅-TPB. (I, M, J, N) Cross-sectional profiles of fluorescence intensity and Gaussian fits (black and red lines, respectively) along the yellow dashed lines in (G), (K), (H), and (L), respectively. Reproduced with permission from ref. 62 and 83, from John Wiley and Sons, Copyright © 2022.

the progressive accumulation of P@FN₉ NPs in the tumor. Moreover, the observation revealed a predominant localization of P@FN₉ NPs in the liver and spleen, suggesting a significant contribution of the reticuloendothelial system to its metabolic pathways. The relatively intense fluorescence from the tumor suggested an increased accumulation of P@FN₉, as shown in Fig. 18G and H. Additionally, the duration of the EPR effect window is assessed by monitoring the blood circulation of P@FN₉. As depicted in Fig. 18F, a significant quantity of P@FN₉ remained present in the bloodstream 12 h post-administration, with a notable decrease observed by 24 h, indicating the effective accumulation of P@FN₉ in the tumor *via* the EPR effect even during the 12–24 h period following administration.

5. Challenges and future prospects

Despite significant advancements in NIR-IIa organic fluorophores, several challenges persist in their development. Firstly,

synthesizing organic fluorophores with emission wavelengths beyond 1300 nm and high fluorescence QYs is challenging due to substantial vibrational overlap between the HOMO and LUMO, which accelerates non-radiative decay pathways, also dubbed the energy gap law.^{66,140} Moreover, it is important to highlight the scarcity of NIR-IIa organic fluorophores with emission maxima higher than 1300 nm as the bottleneck to their future developments in bioimaging. The structural diversity of existing organic fluorophores remains confined primarily to D–A–D, A–D–A, and polymethine architectures, thereby hindering the advancement of NIR-IIa organic fluorophores. The absence of novel molecular scaffolds presents significant challenges in the endeavour to develop effective probes beyond 1300 nm, although existing fluorophores have already been extensively studied to extend emission wavelengths. Therefore, the exploration of new molecular scaffolds or molecular engineering of existing dye molecules could potentially extend the wavelength ranges beyond 1300 nm in future research investigations.¹⁴¹ While advancements have been made in extending





Fig. 16 (A) Depiction of PEGylated P3a and P3c Pdot formation. (B) NIR-II fluorescence hind limb mouse vasculature images captured 5 min after injection of P3a Pdots and P3c Pdots intravenously utilizing a 1319 nm LPF under 808 nm laser excitation. (C) Cross-sectional profile intensity indicated as a white line in (B) for P3a Pdots. (D) Cross-sectional profile intensity along the white line indicated in (B) for P3c Pdots. (E) Mouse brain NIR-II fluorescence imaging at specified time intervals after injection of P3c Pdots intravenously by using a 1250 nm LPF; bottom images were obtained by using a 1319 nm LPF. (F) Cross-sectional profile intensity indicated as a white line in (E); images obtained by using a 1250 nm LPF. (G) Cross-sectional profile intensity indicated as a white line in (E); images obtained by using a 1319 nm LPF. Adapted with permission from ref. 48. John Wiley and Sons, copyright © 2020.

wavelength ranges, a fundamental issue arises with the emission QYs of fluorophores. Currently, most of the NIR-IIa fluorophores exhibit considerably lower QYs than NIR-I fluorophores due to factors such as a small HOMO–LUMO gap, which enables non-radiative decay more than radiative decay, and hence a low emission yield. Thus, achieving an appreciable QY relies fundamentally on the reorganization energy and vibronic coupling.¹⁴² These methods promote radiative decay pathways, thereby overcoming the energy gap law.¹⁴³ Achieving this can also be entailed by specific structural adjustments to fluorophores, such as interacting with biomolecules,¹⁴⁴ imposing conformational constraints,¹¹¹ or introducing large groups that induce steric hindrance.⁶² For example, embedding fluorophores within proteins to form protein–fluorophore complexes could notably elevate the QYs of Pdots. This is attributed to the restricted intermolecular interactions among fluorophores, offering an effective means to enhance their fluorescent brightness.^{144,145} Thus, high-resolution imaging in the NIR-IIa region can be achieved by optimizing both wavelength and brightness through the implementation of mole-

cular engineering strategies applied to the fluorophores. To date, organic fluorophores in the NIR-IIa range are classified into two main types: small molecules and semiconducting polymer dots (SPs), each offering distinct advantages and drawbacks for bioimaging purposes. Small molecule dyes, characterized by their specific structures and lower molecular weights, hold promise for clinical translation due to their potential for renal clearance.¹⁴⁶ However, their complex structures necessitate intricate synthesis and purification procedures. On the other hand, SPs offer easier synthesis routes and purification processes, primarily utilizing well-established palladium-catalyzed Suzuki and Stille coupling reactions.³⁸ Through careful selection of electron donor and acceptor monomers, NIR-II-absorbing SPs can be readily produced. Moreover, SPs exhibit superior photostability compared to small molecule dyes. Looking ahead, addressing the challenges of the synthetic complexity of small molecule dyes while leveraging the synthetic simplicity of SPs' and photostability promises advancements in NIR-IIa bioimaging applications. However, similar to the method of encapsulating






Fig. 17 (A) Depiction of 5H5 NP formation and the structure of 5H5-PEG₈-cRGD_{fk}. (B) Tumour vasculature imaging in the NIR-II and NIR-Ia regions: (i) using 808 nm laser excitation and 1000 LPF with 100 mW cm⁻² (exposure time = 100 ms), and (ii, iii) using 100 mW cm⁻² 1064 nm laser excitation and 1320 LPF (exposure time = 500 ms). (C) Tumor imaging after 48 h: (i) under 808 nm laser irradiation and 1000 LPF (exposure time = 200 ms), or (ii) under 1064 nm laser irradiation and 1320 LPF (1000 ms exposure time). (D) NIR-II and NIR-Ia imaging of U87 glioma tumors with 5H5-PEG₈-cRGD_{fk} captured under 808 nm laser irradiation and 1000 and 1320 nm LPF (exposure time = 100 ms). (E) T/NT of images obtained of the mice bearing the tumor after injection of 5H5-PEG₈-cRGD_{fk} at multiple time intervals. (F and G) Ex vivo fluorescence signals of various tissues/organs after injection of 5H5-PEG₈-cRGD_{fk} into the tumor-bearing mice at 24 h. Images were obtained under 1064 nm laser irradiation with 1320 LPF (exposure time = 500 ms). Adapted with permission from ref. 86. Copyright © 2019, American Chemical Society.

small molecule dyes within a polymer matrix to produce water-soluble nanoparticles, due to SPs' large molecular weight and poor water solubility, encapsulating SPs with amphiphilic copolymers has emerged as a logical approach to create water dispersible semiconducting polymer nanoparticles (Pdots) for biological applications.⁵⁷ Consequently, these probes predominantly exist on the nanoscale, proving advantageous for tumor imaging due to the EPR effect. However, SPs typically exhibit lower NIR-II fluorescence quantum yields compared to small molecule dyes, limiting their application potential. Hence, there is a pressing need to enhance the quantum yield of SPs to unlock their full capabilities in future biomedical endeavours.³⁸

Moving forward, advancements in imaging performance, particularly in terms of spatial and temporal resolution, as well as penetration depth, can be further improved by employing fluorophores capable of emitting beyond the NIR-IIa region. Hence, the advancement of organic fluorophores with extended emission wavelengths, such as those reaching into the NIR-IIb (1500–1700 nm) and NIR-III (2080–2340 nm) regions, presents a promising avenue for exploration in future

research endeavors. However, current limitations in the photo-response of conventional InGaAs detectors restrict optical imaging beyond 1700 nm. Consequently, the NIR-II window is currently delineated as not exceeding beyond 1700 nm, thereby limiting the emission capability of fluorescent dyes beyond this range.³⁵ As we advance into the NIR-IIb/III region, the absorption of light by water becomes a critical consideration. Enhancing the image quality requires the development of NIR-IIb/III emitting dyes with high brightness to withstand attenuation by water.³⁵ The increased water absorption around 1450 nm in the NIR-IIb region can enhance fluorescence image contrast by selectively attenuating photons with longer path lengths through tissue, including multiple scattered photons and fluorescence from deep background structures, which contribute to noise, while preserving ballistic photons that form the image.³⁵ Some research studies have demonstrated high-contrast fluorescence imaging by harnessing the brightness of the tail emission in the NIR-IIb window, but probes with emission maxima in this window have not yet been reported.^{147,148} At present, the *in vivo* fluorescence




Fig. 18 (A) Vascular imaging of mice in the NIR-II range using P@FN9 with various LPFs. (B) NIR-II vascular imaging of mouse hind limb (i) and abdominal (ii) vessels captured using P@FN9 with 1200 nm (left) and 1300 nm (right) LPFs. (C) Fluorescence intensity profiles and Gaussian fits in hind limb (i) and abdominal (ii) vessels obtained using P@FN9. (D) *In vivo* NIR-II imaging of P@FN9 conducted at different time intervals. (E) Fluorescence intensity profile and SBR of tumors observed at different time points ($n = 5$, mean \pm SD). (F) Mean NIR-II fluorescence signals of P@FN9 detected in blood samples collected from mice at various time points ($n = 3$, mean \pm SD). (G) Fluorescence images displaying organs and tumors of mice 24 h post-injection of P@FN9. (H) Fluorescence intensity measured in major organs and tumors of mice 24 h after P@FN9 injection ($n = 3$, mean \pm SD). Adapted with permission from ref. 85. Elsevier, copyright © 2022.

imaging experiments beyond 1700 nm are limited due to the lack of suitable imaging probes and commercially available IR detectors. We eagerly anticipate the future emergence of novel fluorophores, such as long-wavelength-emitting Pdts, and highly efficient detection techniques, like the extended InGaAs camera.³⁹ Despite this, there are currently no NIR-IIa/IIb/III fluorophores approved by the FDA for clinical use. Moreover, with better results in terms of spatiotemporal resolution and tissue penetration depth compared to the FDA-approved ICG-based NIR-I imaging, undoubtedly, significant efforts are required to completely introduce NIR-II imaging technology into clinical settings.³⁹

6. Conclusion

In conclusion, the utilization of NIR-IIa fluorescent polymer dots (Pdts) for deep-tissue biomedical imaging presents a compelling avenue for advancing real-time bioimaging and facilitating future image-guided surgery. This promise is underpinned by their remarkable SBR, attributed to reduced light scattering, tissue absorption, and minimal autofluorescence. Notably, Pdts exhibit superior fluorescence brightness, exceptional biocompatibility, stability, and facile functionalization, rendering them indispensable across a spectrum of *in vivo* bioimaging applications. This review systematically delineates recent advancements in engineering and designing

various classes of NIR-IIa organic fluorophores, with a particular emphasis on prevalent molecular frameworks such as D–A and polymethine. Key strategies for redshifting emission wavelengths while preserving high brightness encompass the incorporation of stronger donors and/or acceptors, extension of conjugation systems, formation of J-aggregates, and introduction of bulky counter-ions. However, the pervasive challenge of “quenching” presents a fundamental hurdle to achieving brighter Pdts. Effective strategies discussed include the integration of bulky shielding units, anti-aggregation caused by ACQ units, or adding AIE units into the molecular framework backbones or side chains. Besides, research findings have revealed that small molecule dyes offer promise for clinical translation due to potential renal clearance, despite complex synthesis procedures. Conversely, SPs boast easier synthesis and superior photostability but face challenges regarding quantum yield and water solubility. Encapsulating SPs with amphiphilic copolymers to form Pdts addresses solubility issues but requires improvements in quantum yield by considering effective molecular engineering strategies as discussed earlier for broader biomedical applications. Looking ahead, while organic materials have gained extensive utilization in laboratory environments, their translation into clinical applications remains constrained. Addressing extant challenges is imperative to facilitate their seamless integration into clinical practice. Therefore, there is an urgent need to develop novel organic molecules capable of circumventing these impedi-



ments, thereby unlocking their full potential in clinical settings. By overcoming these barriers, the field stands poised to realize transformative strides in deep-tissue biomedical imaging, ultimately enhancing diagnostic accuracy and therapeutic interventions.

Conflicts of interest

There are no conflicts to declare.

References

- 1 B.-S. Rachel, Y. Nikolai, G. Ludmila, G. Diana, F. Alex, K. Abraham, A. Hernan, K. Zohar and I. Ora, *J. Nucl. Med.*, 2003, **44**, 1200.
- 2 A. Galperin, D. Margel, J. Baniel, G. Dank, H. Biton and S. Margel, *Biomaterials*, 2007, **28**, 4461–4468.
- 3 U. R. Acharya, S. V. Sree, M. R. K. Mookiah, L. Saba, H. Gao, G. Mallarini and J. S. Suri, *Proc. Inst. Mech. Eng., Part H*, 2013, **227**, 643–654.
- 4 E. Terreno, D. D. Castelli, A. Viale and S. Aime, *Chem. Rev.*, 2010, **110**, 3019–3042.
- 5 G. Rousseau, A. Blouin and J.-P. Monchalain, *Opt. Express*, 2008, **16**, 12577–12590.
- 6 B. Dong, C. Sun and H. F. Zhang, *IEEE Trans. Biomed. Eng.*, 2017, **64**, 4–15.
- 7 J. P. Bernd, K. Armin, N. Thomas and S. Heinz-Peter, *J. Nucl. Med.*, 2010, **51**, 333.
- 8 O. M. Merkel, D. Librizzi, A. Pfestroff, T. Schurrat, M. Béhé and T. Kissel, *Bioconjugate Chem.*, 2009, **20**, 174–182.
- 9 L. B. Dale and P. W. Kathy, *J. Nucl. Med.*, 2013, **54**, 83.
- 10 A. Refaat, M. L. Yap, G. Pietersz, A. P. G. Walsh, J. Zeller, B. del Rosal, X. Wang and K. Peter, *J. Nanobiotechnol.*, 2022, **20**, 450.
- 11 P.-Y. You, F.-C. Li, M.-H. Liu and Y.-H. Chan, *ACS Appl. Mater. Interfaces*, 2019, **11**, 9841–9849.
- 12 F. Ye, C. Wu, Y. Jin, Y.-H. Chan, X. Zhang and D. T. Chiu, *J. Am. Chem. Soc.*, 2011, **133**, 8146–8149.
- 13 L. D. Adair and E. J. New, *Curr. Opin. Biotechnol.*, 2023, **83**, 102973.
- 14 B. Huang, M. Bates and X. Zhuang, *Annu. Rev. Biochem.*, 2009, **78**, 993–1016.
- 15 W. Li, G. S. Kaminski Schierle, B. Lei, Y. Liu and C. F. Kaminski, *Chem. Rev.*, 2022, **122**, 12495–12543.
- 16 D. Bourgeois, *Commun. Biol.*, 2023, **6**, 53.
- 17 S. Shih-Po, L. Yun-Chen, L. Syue-Liang, L. Yi-Xuan, L. Min-Ying, C. Yang-Hsiang, L. Yi-Jang, Y. Muh-Hwa and C. Huihua Kenny, *J. Biomed. Opt.*, 2023, **28**, 094807.
- 18 K.-F. Hsu, S.-P. Su, H.-F. Lu, M.-H. Liu, Y. J. Chang, Y.-J. Lee, H. K. Chiang, C.-P. Hsu, C.-W. Lu and Y.-H. Chan, *Chem. Sci.*, 2022, **13**, 10074–10081.
- 19 G. M. van Dam, G. Themelis, L. M. A. Crane, N. J. Harlaar, R. G. Pleijhuis, W. Kelder, A. Sarantopoulos, J. S. de Jong, H. J. G. Arts, A. G. J. van der Zee, J. Bart, P. S. Low and V. Ntziachristos, *Nat. Med.*, 2011, **17**, 1315–1319.
- 20 A. L. Vahrmeijer, M. Hutteman, J. R. van der Vorst, C. J. H. van de Velde and J. V. Frangioni, *Nat. Rev. Clin. Oncol.*, 2013, **10**, 507–518.
- 21 Y.-C. Hsieh, K.-W. Guo, M.-W. Wang, S.-P. Su, Y.-H. Syu, C.-S. Huang and Y.-H. Chan, *Ann. Surg. Oncol.*, 2023, **30**, 8419–8427.
- 22 S. Hernot, L. van Manen, P. Debie, J. S. D. Mieog and A. L. Vahrmeijer, *Lancet Oncol.*, 2019, **20**, e354–e367.
- 23 S. L. Troyan, V. Kianzad, S. L. Gibbs-Strauss, S. Gioux, A. Matsui, R. Oketokoun, L. Ngo, A. Khamene, F. Azar and J. V. Frangioni, *Ann. Surg. Oncol.*, 2009, **16**, 2943–2952.
- 24 R. Weissleder, *Nat. Biotechnol.*, 2001, **19**, 316–317.
- 25 V. J. Pansare, S. Hejazi, W. J. Faenza and R. K. Prud'homme, *Chem. Mater.*, 2012, **24**, 812–827.
- 26 J. Li and K. Pu, *Chem. Soc. Rev.*, 2019, **48**, 38–71.
- 27 M. V. Padalkar and N. Pleshko, *Analyst*, 2015, **140**, 2093–2100.
- 28 A. N. Bashkatov, E. A. Genina, V. I. Kochubey and V. V. Tuchin, *J. Phys. D: Appl. Phys.*, 2005, **38**, 2543.
- 29 X. Dang, N. M. Bardhan, J. Qi, L. Gu, N. A. Eze, C.-W. Lin, S. Kataria, P. T. Hammond and A. M. Belcher, *Sci. Rep.*, 2019, **9**, 3873.
- 30 R. Wang, X. Li, L. Zhou and F. Zhang, *Angew. Chem., Int. Ed.*, 2014, **53**, 12086–12090.
- 31 K. Welsher, Z. Liu, S. P. Sherlock, J. T. Robinson, Z. Chen, D. Daranciang and H. Dai, *Nat. Nanotechnol.*, 2009, **4**, 773–780.
- 32 A. M. Smith, M. C. Mancini and S. Nie, *Nat. Nanotechnol.*, 2009, **4**, 710–711.
- 33 Y.-X. Li, S.-P. Su, C.-H. Yang, M.-H. Liu, P.-H. Lo, Y.-C. Chen, C.-P. Hsu, Y.-J. Lee, H. K. Chiang and Y.-H. Chan, *Adv. Healthcare Mater.*, 2021, **10**, 2100993.
- 34 A. Sun, H. Guo, Q. Gan, L. Yang, Q. Liu and L. Xi, *Opt. Express*, 2020, **28**, 9002–9013.
- 35 Z. Feng, T. Tang, T. Wu, X. Yu, Y. Zhang, M. Wang, J. Zheng, Y. Ying, S. Chen, J. Zhou, X. Fan, D. Zhang, S. Li, M. Zhang and J. Qian, *Light: Sci. Appl.*, 2021, **10**, 197.
- 36 J. A. Carr, M. Aellen, D. Franke, P. T. C. So, O. T. Bruns and M. G. Bawendi, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**, 9080–9085.
- 37 G. Hong, S. Diao, J. Chang, A. L. Antaris, C. Chen, B. Zhang, S. Zhao, D. N. Atochin, P. L. Huang, K. I. Andreasson, C. J. Kuo and H. Dai, *Nat. Photonics*, 2014, **8**, 723–730.
- 38 Y. Liu, Y. Li, S. Koo, Y. Sun, Y. Liu, X. Liu, Y. Pan, Z. Zhang, M. Du, S. Lu, X. Qiao, J. Gao, X. Wang, Z. Deng, X. Meng, Y. Xiao, J. S. Kim and X. Hong, *Chem. Rev.*, 2022, **122**, 209–268.
- 39 C. Li, G. Chen, Y. Zhang, F. Wu and Q. Wang, *J. Am. Chem. Soc.*, 2020, **142**, 14789–14804.
- 40 J.-J. Zhang, Y. Lin, H. Zhou, H. He, J.-J. Ma, M.-Y. Luo, Z.-L. Zhang and D.-W. Pang, *Adv. Healthcare Mater.*, 2019, **8**, 1900341.



- 41 Z.-Y. Liu, A.-A. Liu, H. Fu, Q.-Y. Cheng, M.-Y. Zhang, M.-M. Pan, L.-P. Liu, M.-Y. Luo, B. Tang, W. Zhao, J. Kong, X. Shao and D.-W. Pang, *J. Am. Chem. Soc.*, 2021, **143**, 12867–12877.
- 42 O. T. Bruns, T. S. Bischof, D. K. Harris, D. Franke, Y. Shi, L. Riedemann, A. Bartelt, F. B. Jaworski, J. A. Carr, C. J. Rowlands, M. W. B. Wilson, O. Chen, H. Wei, G. W. Hwang, D. M. Montana, I. Coropceanu, O. B. Achorn, J. Kloepper, J. Heeren, P. T. C. So, D. Fukumura, K. F. Jensen, R. K. Jain and M. G. Bawendi, *Nat. Biomed. Eng.*, 2017, **1**, 0056.
- 43 Y. Zhang, H. Yang, X. An, Z. Wang, X. Yang, M. Yu, R. Zhang, Z. Sun and Q. Wang, *Small*, 2020, **16**, 2001003.
- 44 Y. Zhong and H. Dai, *Nano Res.*, 2020, **13**, 1281–1294.
- 45 W. Shao, G. Chen, A. Kuzmin, H. L. Kutscher, A. Pliss, T. Y. Ohulchanskyy and P. N. Prasad, *J. Am. Chem. Soc.*, 2016, **138**, 16192–16195.
- 46 S. He, S. Chen, D. Li, Y. Wu, X. Zhang, J. Liu, J. Song, L. Liu, J. Qu and Z. Cheng, *Nano Lett.*, 2019, **19**, 2985–2992.
- 47 G. Qian, B. Dai, M. Luo, D. Yu, J. Zhan, Z. Zhang, D. Ma and Z. Y. Wang, *Chem. Mater.*, 2008, **20**, 6208–6216.
- 48 Z. Zhang, X. Fang, Z. Liu, H. Liu, D. Chen, S. He, J. Zheng, B. Yang, W. Qin, X. Zhang and C. Wu, *Angew. Chem., Int. Ed.*, 2020, **59**, 3691–3698.
- 49 M.-H. Liu, Z. Zhang, Y.-C. Yang and Y.-H. Chan, *Angew. Chem., Int. Ed.*, 2021, **60**, 983–989.
- 50 P. Chowdhury and Y.-H. Chan, *Mol. Syst. Des. Eng.*, 2022, **7**, 702–719.
- 51 N. Gupta, Y.-H. Chan, S. Saha and M.-H. Liu, *Chem. – Asian J.*, 2021, **16**, 175–184.
- 52 M.-H. Liu, T.-C. Chen, J. R. Vicente, C.-N. Yao, Y.-C. Yang, C.-P. Chen, P.-W. Lin, Y.-C. Ho, J. Chen, S.-Y. Lin and Y.-H. Chan, *ACS Appl. Bio Mater.*, 2020, **3**, 3846–3858.
- 53 D. M. Mayder, C. M. Tonge, G. D. Nguyen, M. V. Tran, G. Tom, G. H. Darwish, R. Gupta, K. Lix, S. Kamal, W. R. Algar, S. A. Burke and Z. M. Hudson, *J. Am. Chem. Soc.*, 2021, **143**, 16976–16992.
- 54 X. Bai, K. Wang, L. Chen, J. Zhou and J. Wang, *J. Mater. Chem. B*, 2022, **10**, 6248–6262.
- 55 R. Gupta, W. J. Peveler, K. Lix and W. R. Algar, *Anal. Chem.*, 2019, **91**, 10955–10960.
- 56 C. Wu, T. Schneider, M. Zeigler, J. Yu, P. G. Schiro, D. R. Burnham, J. D. McNeill and D. T. Chiu, *J. Am. Chem. Soc.*, 2010, **132**, 15410–15417.
- 57 L. Feng, C. Zhu, H. Yuan, L. Liu, F. Lv and S. Wang, *Chem. Soc. Rev.*, 2013, **42**, 6620–6633.
- 58 C. Wu, S. J. Hansen, Q. Hou, J. Yu, M. Zeigler, Y. Jin, D. R. Burnham, J. D. McNeill, J. M. Olson and D. T. Chiu, *Angew. Chem., Int. Ed.*, 2011, **50**, 3430–3434.
- 59 W.-K. Tsai and Y.-H. Chan, *J. Chin. Chem. Soc.*, 2019, **66**, 9–20.
- 60 C.-S. Ke, C.-C. Fang, J.-Y. Yan, P.-J. Tseng, J. R. Pyle, C.-P. Chen, S.-Y. Lin, J. Chen, X. Zhang and Y.-H. Chan, *ACS Nano*, 2017, **11**, 3166–3177.
- 61 M. Verma, Y.-H. Chan, S. Saha and M.-H. Liu, *ACS Appl. Bio Mater.*, 2021, **4**, 2142–2159.
- 62 Y. Yang, C. Sun, S. Wang, K. Yan, M. Zhao, B. Wu and F. Zhang, *Angew. Chem., Int. Ed.*, 2022, **61**, e202117436.
- 63 Y. Dai, Z. Sun, H. Zhao, D. Qi, X. Li, D. Gao, M. Li, Q. Fan, Q. Shen and W. Huang, *Biomaterials*, 2021, **275**, 120935.
- 64 W. Zhang, W. Deng, H. Zhang, X. Sun, T. Huang, W. Wang, P. Sun, Q. Fan and W. Huang, *Biomaterials*, 2020, **243**, 119934.
- 65 W. Zhang, T. Huang, J. Li, P. Sun, Y. Wang, W. Shi, W. Han, W. Wang, Q. Fan and W. Huang, *ACS Appl. Mater. Interfaces*, 2019, **11**, 16311–16319.
- 66 R. Englman and J. Jortner, *Mol. Phys.*, 1970, **18**, 145–164.
- 67 Z. Lei and F. Zhang, *Angew. Chem., Int. Ed.*, 2021, **60**, 16294–16308.
- 68 G. H. Lee, M. G. Han, D.-S. Leem, S.-J. Lim, S. Yun, K.-H. Lee, X. Bulliard, K.-B. Park, T. Yagi, Y. S. Choi, Y. W. Jin and S. Lee, *J. Phys. Chem. C*, 2016, **120**, 10176–10184.
- 69 Q. Yang, Z. Hu, S. Zhu, R. Ma, H. Ma, Z. Ma, H. Wan, T. Zhu, Z. Jiang, W. Liu, L. Jiao, H. Sun, Y. Liang and H. Dai, *J. Am. Chem. Soc.*, 2018, **140**, 1715–1724.
- 70 A. Ji, H. Lou, C. Qu, W. Lu, Y. Hao, J. Li, Y. Wu, T. Chang, H. Chen and Z. Cheng, *Nat. Commun.*, 2022, **13**, 3815.
- 71 W. Wu, Y. Yang, Y. Yang, Y. Yang, K. Zhang, L. Guo, H. Ge, X. Chen, J. Liu and H. Feng, *Small*, 2019, **15**, 1805549.
- 72 F. Würthner, T. E. Kaiser and C. R. Saha-Möller, *Angew. Chem., Int. Ed.*, 2011, **50**, 3376–3410.
- 73 X.-D. Zhang, H. Wang, A. L. Antaris, L. Li, S. Diao, R. Ma, A. Nguyen, G. Hong, Z. Ma, J. Wang, S. Zhu, J. M. Castellano, T. Wyss-Coray, Y. Liang, J. Luo and H. Dai, *Adv. Mater.*, 2016, **28**, 6872–6879.
- 74 R. Tian, H. Ma, Q. Yang, H. Wan, S. Zhu, S. Chandra, H. Sun, D. O. Kiesewetter, G. Niu, Y. Liang and X. Chen, *Chem. Sci.*, 2019, **10**, 326–332.
- 75 Y. Liu, J. Liu, D. Chen, X. Wang, Z. Zhang, Y. Yang, L. Jiang, W. Qi, Z. Ye, S. He, Q. Liu, L. Xi, Y. Zou and C. Wu, *Angew. Chem., Int. Ed.*, 2020, **59**, 21049–21057.
- 76 Q. Zhao, H. Lai, H. Chen, H. Li and F. He, *J. Mater. Chem. A*, 2021, **9**, 1119–1126.
- 77 X. Zhao, F. Zhang and Z. Lei, *Chem. Sci.*, 2022, **13**, 11280–11293.
- 78 Q. Yang, H. Ma, Y. Liang and H. Dai, *Acc. Mater. Res.*, 2021, **2**, 170–183.
- 79 M. Levitus and S. Ranjit, *Q. Rev. Biophys.*, 2011, **44**, 123–151.
- 80 L. An, L. Zheng, Z. Zhao, X. Qu, C. Liang, C. Ou, X. Mou, X. Dong and Y. Cai, *J. Mater. Chem. B*, 2023, **11**, 8456–8463.
- 81 F. Ye, W. Huang, C. Li, G. Li, W.-C. Yang, S. H. Liu, J. Yin, Y. Sun and G.-F. Yang, *Adv. Ther.*, 2020, **3**, 2000170.
- 82 S. Chen, B. Sun, H. Miao, G. Wang, P. Sun, J. Li, W. Wang, Q. Fan and W. Huang, *ACS Mater. Lett.*, 2020, **2**, 174–183.
- 83 S. Chen, Y. Pan, K. Chen, P. Chen, Q. Shen, P. Sun, W. Hu and Q. Fan, *Angew. Chem., Int. Ed.*, 2023, **62**, e202215372.
- 84 C. Sun, B. Li, M. Zhao, S. Wang, Z. Lei, L. Lu, H. Zhang, L. Feng, C. Dou, D. Yin, H. Xu, Y. Cheng and F. Zhang, *J. Am. Chem. Soc.*, 2019, **141**, 19221–19225.



- 85 C. Teng, H. Dang, S. Zhang, Y. Xu, D. Yin and L. Yan, *Acta Biomater.*, 2022, **154**, 572–582.
- 86 B. Ding, Y. Xiao, H. Zhou, X. Zhang, C. Qu, F. Xu, Z. Deng, Z. Cheng and X. Hong, *J. Med. Chem.*, 2019, **62**, 2049–2059.
- 87 Y. C. T. Huang, P.-F. Sun, Q.-L. Fan and W. Huang, *Acta Polym. Sin.*, 2020, **51**, 346–354.
- 88 C. Yin, X. Tai, X. Li, J. Tan, C.-S. Lee, P. Sun, Q. Fan and W. Huang, *Chem. Eng. J.*, 2022, **428**, 132098.
- 89 Y. Dai, H. Zhao, K. He, W. Du, Y. Kong, Z. Wang, M. Li, Q. Shen, P. Sun and Q. Fan, *Small*, 2021, **17**, 2102527.
- 90 X. Song, X. Lu, B. Sun, H. Zhang, P. Sun, H. Miao, Q. Fan and W. Huang, *ACS Appl. Polym. Mater.*, 2020, **2**, 4171–4179.
- 91 Y. Dai, D. Leng, Z. Guo, J. Wang, Y. Gu, Y. Peng, L. Zhu and Q. Zhao, *Chem. Eng. J.*, 2024, **479**, 147704.
- 92 C. S. Sarap, Y. Singh, J. M. Lane and N. Rai, *Sci. Rep.*, 2023, **13**, 21587.
- 93 I. Fureraaj, D. S. Budkina and E. Vauthey, *Phys. Chem. Chem. Phys.*, 2022, **24**, 25979–25989.
- 94 N. I. Nijegorodov and W. S. Downey, *J. Phys. Chem.*, 1994, **98**, 5639–5643.
- 95 J. Sjöqvist, M. Linares, M. Lindgren and P. Norman, *Phys. Chem. Chem. Phys.*, 2011, **13**, 17532–17542.
- 96 J. A. Carr, D. Franke, J. R. Caram, C. F. Perkinson, M. Saif, V. Askoxylakis, M. Datta, D. Fukumura, R. K. Jain, M. G. Bawendi and O. T. Bruns, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**, 4465–4470.
- 97 P.-A. Bouit, C. Aronica, L. Toupet, B. Le Guennic, C. Andraud and O. Maury, *J. Am. Chem. Soc.*, 2010, **132**, 4328–4335.
- 98 M. Eskandari, J. C. Roldao, J. Cerezo, B. Milián-Medina and J. Gierschner, *J. Am. Chem. Soc.*, 2020, **142**, 2835–2843.
- 99 J. Gayton, S. A. Autry, W. Meador, S. R. Parkin, G. A. Hill Jr., N. I. Hammer and J. H. Delcamp, *J. Org. Chem.*, 2019, **84**, 687–697.
- 100 C. Sun, M. Zhao, X. Zhu, P. Pei and F. Zhang, *CCS Chem.*, 2021, **4**, 476–486.
- 101 X. Ma, Y. Huang, A. Abedi Syed Ali, H. Kim, B. Davin Tan Teck, X. Liu, W.-C. Yang, Y. Sun, H. Liu Sheng, J. Yin, J. Yoon and G.-F. Yang, *CCS Chem.*, 2022, **4**, 1961–1976.
- 102 E. E. Jelley, *Nature*, 1936, **138**, 1009–1010.
- 103 W. Cao and E. M. Sletten, *J. Am. Chem. Soc.*, 2018, **140**, 2727–2730.
- 104 N. Dar and R. Ankari, *ChemistryOpen*, 2022, **11**, e202200103.
- 105 J. Luo, Z. Xie, J. W. Y. Lam, L. Cheng, H. Chen, C. Qiu, H. S. Kwok, X. Zhan, Y. Liu, D. Zhu and B. Z. Tang, *Chem. Commun.*, 2001, 1740–1741, DOI: [10.1039/B105159H](https://doi.org/10.1039/B105159H).
- 106 F. Würthner, *Angew. Chem., Int. Ed.*, 2020, **59**, 14192–14196.
- 107 J. L. Bricks, Y. L. Slominskii, I. D. Panas and A. P. Demchenko, *Methods Appl. Fluoresc.*, 2018, **6**, 012001.
- 108 C. Yang, X. Wang, M. Wang, K. Xu and C. Xu, *Chem. – Eur. J.*, 2017, **23**, 4310–4319.
- 109 L. D. Lavis and R. T. Raines, *ACS Chem. Biol.*, 2014, **9**, 855–866.
- 110 S. Liu, H. Ou, Y. Li, H. Zhang, J. Liu, X. Lu, R. T. K. Kwok, J. W. Y. Lam, D. Ding and B. Z. Tang, *J. Am. Chem. Soc.*, 2020, **142**, 15146–15156.
- 111 S. M. Usama, T. Thompson and K. Burgess, *Angew. Chem., Int. Ed.*, 2019, **58**, 8974–8976.
- 112 S. S. Matikonda, G. Hammersley, N. Kumari, L. Grabenhorst, V. Glembockyte, P. Tinnefeld, J. Ivanic, M. Levitus and M. J. Schnermann, *J. Org. Chem.*, 2020, **85**, 5907–5915.
- 113 E. D. Cosco, B. A. Arús, A. L. Spearman, T. L. Atallah, I. Lim, O. S. Leland, J. R. Caram, T. S. Bischof, O. T. Bruns and E. M. Sletten, *J. Am. Chem. Soc.*, 2021, **143**, 6836–6846.
- 114 A. Martin and P. Rivera-Fuentes, *Nat. Chem.*, 2024, **16**, 28–35.
- 115 N. B. Alexey, V. B. Kirill, N. D. Konstantin, L. C. Maria, A. G. Elina, D. G. Vadim, I. K. Vyacheslav, N. L. Ekaterina, B. P. Alexander, E. S. Marina, A. T. Polina, K. T. Daria, D. Y. Dmitry, A. Y. Dmitry, Y. Irina Yu, S. Z. Olga and V. T. Valery, *J. Biomed. Opt.*, 2018, **23**, 091416.
- 116 G. Hong, A. L. Antaris and H. Dai, *Nat. Biomed. Eng.*, 2017, **1**, 0010.
- 117 K. Li and B. Liu, *Chem. Soc. Rev.*, 2014, **43**, 6570–6597.
- 118 Z. Li, P.-Z. Liang, T.-B. Ren, L. Yuan and X.-B. Zhang, *Angew. Chem., Int. Ed.*, 2023, **62**, e202305742.
- 119 A. A. Bogdanov, R. Weissleder and T. J. Brady, *Adv. Drug Delivery Rev.*, 1995, **16**, 335–348.
- 120 R. Zhang, Z. Bi, L. Zhang, H. Yang, H. Wang, W. Zhang, Z. Qiu, C. Zhang, Y. Xiong, Y. Li, Z. Zhao and B. Z. Tang, *ACS Nano*, 2023, **17**, 19265–19274.
- 121 J. T. Alander, I. Kaartinen, A. Laakso, T. Pätälä, T. Spillmann, V. V. Tuchin, M. Venermo and P. Välsuö, *Int. J. Biomed. Imaging*, 2012, **2012**, 940585.
- 122 J. V. Frangioni, *Curr. Opin. Chem. Biol.*, 2003, **7**, 626–634.
- 123 M. Gupta, K. Shrivastava, V. Raghuvanshi, S. Ojha, A. Gupta and S. Sasidhar, *J. Oral Maxillofac. Pathol.*, 2019, **23**, 304.
- 124 P. Carmeliet and R. K. Jain, *Nature*, 2000, **407**, 249–257.
- 125 D. O. Bates, D. Lodwick and B. Williams, *Microcirculation*, 1999, **6**, 83–96.
- 126 S. Li, H. Chen, H. Liu, L. Liu, Y. Yuan, C. Mao, W. Zhang, X. Zhang, W. Guo, C.-S. Lee and X.-J. Liang, *ACS Nano*, 2020, **14**, 13681–13690.
- 127 G. Hong, J. C. Lee, J. T. Robinson, U. Raaz, L. Xie, N. F. Huang, J. P. Cooke and H. Dai, *Nat. Med.*, 2012, **18**, 1841–1846.
- 128 Z. Feng, Y. Li, S. Chen, J. Li, T. Wu, Y. Ying, J. Zheng, Y. Zhang, J. Zhang, X. Fan, X. Yu, D. Zhang, B. Z. Tang and J. Qian, *Nat. Commun.*, 2023, **14**, 5017.
- 129 S. Yidan, Z. Xingjian and M. D. Allison, *J. Biomed. Opt.*, 2023, **28**, 094805.
- 130 W. Wang, X. He, M. Du, C. Xie, W. Zhou, W. Huang and Q. Fan, *Front. Chem.*, 2021, **9**, 769655.
- 131 B. Li, M. Zhao, L. Feng, C. Dou, S. Ding, G. Zhou, L. Lu, H. Zhang, F. Chen, X. Li, G. Li, S. Zhao, C. Jiang, Y. Wang,



- D. Zhao, Y. Cheng and F. Zhang, *Nat. Commun.*, 2020, **11**, 3102.
- 132 C. Li, Y. Zhang, M. Wang, Y. Zhang, G. Chen, L. Li, D. Wu and Q. Wang, *Biomaterials*, 2014, **35**, 393–400.
- 133 R. L. Siegel, K. D. Miller, N. S. Wagle and A. Jemal, *CA-Cancer J. Clin.*, 2023, **73**, 17–48.
- 134 I. I. Wistuba, J. G. Gelovani, J. J. Jacoby, S. E. Davis and R. S. Herbst, *Nat. Rev. Clin. Oncol.*, 2011, **8**, 135–141.
- 135 P. Wang, Y. Fan, L. Lu, L. Liu, L. Fan, M. Zhao, Y. Xie, C. Xu and F. Zhang, *Nat. Commun.*, 2018, **9**, 2898.
- 136 S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak and W. C. W. Chan, *Nat. Rev. Mater.*, 2016, **1**, 16014.
- 137 R. K. Jain, *Annu. Rev. Biomed. Eng.*, 1999, **1**, 241–263.
- 138 S. Sindhvani, A. M. Syed, J. Ngai, B. R. Kingston, L. Maiorino, J. Rothschild, P. MacMillan, Y. Zhang, N. U. Rajesh, T. Hoang, J. L. Y. Wu, S. Wilhelm, A. Zilman, S. Gadde, A. Sulaiman, B. Ouyang, Z. Lin, L. Wang, M. Egeblad and W. C. W. Chan, *Nat. Mater.*, 2020, **19**, 566–575.
- 139 S. D. Perrault, C. Walkey, T. Jennings, H. C. Fischer and W. C. W. Chan, *Nano Lett.*, 2009, **9**, 1909–1915.
- 140 S. Wang, B. Li and F. Zhang, *ACS Cent. Sci.*, 2020, **6**, 1302–1316.
- 141 P. Chowdhury, Z.-Y. Lu, S.-P. Su, M.-H. Liu, C.-Y. Lin, M.-W. Wang, Y.-C. Luo, Y.-J. Lee, H. K. Chiang and Y.-H. Chan, *Adv. Healthcare Mater.*, 2024, 2400606.
- 142 H.-M. Pan, C.-C. Wu, C.-Y. Lin, C.-S. Hsu, Y.-C. Tsai, P. Chowdhury, C.-H. Wang, K.-H. Chang, C.-H. Yang, M.-H. Liu, Y.-C. Chen, S.-P. Su, Y.-J. Lee, H. K. Chiang, Y.-H. Chan and P.-T. Chou, *J. Am. Chem. Soc.*, 2023, **145**, 516–526.
- 143 C.-C. Wu, E. Y. Li and P.-T. Chou, *Chem. Sci.*, 2022, **13**, 7181–7189.
- 144 A. L. Antaris, H. Chen, S. Diao, Z. Ma, Z. Zhang, S. Zhu, J. Wang, A. X. Lozano, Q. Fan, L. Chew, M. Zhu, K. Cheng, X. Hong, H. Dai and Z. Cheng, *Nat. Commun.*, 2017, **8**, 15269.
- 145 C. Li and Q. Wang, *ACS Nano*, 2018, **12**, 9654–9659.
- 146 J. Huang, C. Xie, X. Zhang, Y. Jiang, J. Li, Q. Fan and K. Pu, *Angew. Chem., Int. Ed.*, 2019, **58**, 15120–15127.
- 147 S. Lu, L. Xue, M. Yang, J. Wang, Y. Li, Y. Jiang, X. Hong, M. Wu and Y. Xiao, *Nano Res.*, 2022, **15**, 9183–9191.
- 148 Y. Li, Y. Liu, Q. Li, X. Zeng, T. Tian, W. Zhou, Y. Cui, X. Wang, X. Cheng, Q. Ding, X. Wang, J. Wu, H. Deng, Y. Li, X. Meng, Z. Deng, X. Hong and Y. Xiao, *Chem. Sci.*, 2020, **11**, 2621–2626.

